Title:

Bezisterim-associated anti-inflammatory epigenetic modulation of age acceleration and Alzheimer's disease genes

Short title:

Reduced epigenetic age with bezisterim

Authors:

Christopher Reading[1] Jiayan Yan[1], Clarence Ahlem[1], Penelope Markham[1], Stephen O'Quinn[1], Joe M. Palumbo[1], Varun B. Dwaraka[2*]

[1]BioVie Inc., Carson City, NV, USA; [2]TruDiagnostic, Inc., Lexington, KY, USA

*Corresponding author

Varun B. Dwaraka

TruDiagnostic, Inc.

Lexington, KY, USA

Email: varun.dwaraka@trudiagnostic.com

ORCID: https://orcid.org/0000-0001-9033-3092

Abstract

Age is the predominant risk factor for late-onset Alzheimer's disease, and interventions that reduce biological age may be therapeutic. We previously reported that bezisterim, a novel anti-inflammatory insulin sensitizer, modulated epigenetic age acceleration (EAA) in a randomized, placebo-controlled, 7-month Alzheimer's disease trial. Building on prior evidence linking bezisterim-induced EAA changes to improved cognitive and functional outcomes, we conducted integrative analyses to elucidate underlying molecular mechanisms. Bezisterim significantly reduced EAA across 12 independent biological clocks, reinforcing its impact on validated aging biomarkers, and identifying targets predominantly involved in inflammation and cognition, including transcriptional regulators that orchestrate broader gene networks. Genome-wide methylation profiling revealed 2,154 genes with significant differential promoter methylation between bezisterim and placebo groups. Treatment increased promoter methylation – suggesting transcriptional repression – in 433 genes known to be associated with aging and disease processes, including microglial neuroinflammation, pro-inflammatory kinase activity, cognitive decline, lipid metabolism, and transcriptional regulation. Conversely, treatment-decreased methylation of 15 genes potentially improved autophagy and increased anti-inflammatory phosphatases and macrophage polarization. Analyses were conducted to search for correlations between promoter methylation and the 31 previous clinical measures in bezisterim and placebo subjects. Significant correlations (72 bezisterim, 13 placebo) suggest that methylation differences contribute to observed clinical differences. The majority of the correlations in bezisterim subjects were associated with neurologic and metabolic improvements, and 12 of 72 were correlated with 2-5 clinical measures each, potentially emphasizing their contribution to clinical benefit. Bezisterim appears to exert pleiotropic effects through coordinated modulation of aging-related epigenetic programs, potentially counteracting neurodegenerative processes at the intersection of inflammation, metabolism, and transcriptional control.

Keywords

Aging clocks, Alzheimer's disease, bezisterim, DNA-methylation, epigenetics, neuroinflammation

1. Introduction

Familial Alzheimer's disease (AD) genetics clearly implicate amyloid beta (Aβ) formation as causative, but late-onset AD (LOAD) is associated with large numbers of mutations including many in lipids and innate immune pathways. The number one risk factor for LOAD is age. Koch's hypothesis does not support the "Amyloid Hypothesis" in LOAD, since a significant fraction of post-mortem AD brains lack Aβ plaques, and a significant fraction of non-demented post-mortem brains have Aβ plaques (Cunningham & Hennessy, 2015). The Amyloid Hypothesis suggests that removing Aβ should halt AD progression, but this has not been the case. The Alzheimer's Disease Neuroimaging Initiative (ADNI) amyloid-tau index (ATI) criteria suggest that inflammation needs to be considered in AD pathophysiology (Aisen, 2024).

Inflammation is often interpreted within the framework of infections, but sterile inflammation is the result of metabolic dysregulation with presentation of danger signals (damage-associated molecular patterns [DAMPs]) that trigger innate immune system responses, predominantly in macrophages and microglia. The activation of pro-inflammatory kinase cascades triggering nuclear factor kappa B (NFκB) and the node-like receptor protein 3 (NLRP3) inflammasome lead to activation of cytokines and chemokines. Aβ and phosphorylated tau (pTau) are danger signals that trigger damage- or disease-associated microglia (DAM) (Deczkowska et al., 2018; Y. Wei & Li, 2022), accelerated aging, and altered transcriptional profiles (Srinivasan et al., 2020). Inflammation is now recognized as a central mechanism in AD, and there is evidence that decreasing age-related inflammation can alter the progression of AD (Kinney et al., 2018).

Macrophages and microglia exist in continuums, from M0 (normal state) to either M1 (pro-inflammatory) or M2 (restorative). Inflammatory activation is associated with polarization from M0 to M1, and this transition is associated with a switch in glucose metabolism from oxidative phosphorylation to glycolysis (termed the Warburg effect in cancer) (Liberti & Locasale, 2016). Once activated in tissue, myeloid cells, including macrophages, Kupffer cells and microglia, drive inflammation until the danger signal is resolved. By contrast, DAMPs are not easily resolved, and persist in creating a chronic low-grade state of metabolic inflammation. This results in activation of macrophages and microglia, inflammatory inhibition of insulin signaling, increases in glycolysis, inflammatory lipid synthesis, pro-inflammatory kinase cascades, and transcription factors (TFs).

Although molecular pathways have been clarified for Aβ and pTau DAMPs, the complexity of microglial neuroinflammation and the contributions of systemic low-grade inflammation to AD progression remain less clear. The molecular inflammation networks involved in neurodegeneration are known to overlap with other diseases of aging, including diabetes, obesity, and cardiovascular disease. Recently, systems biology approaches have been applied to attempt to elucidate the relationship between DNA methylation, gene transcript expression, proteomics, and metabolic inflammation pathways.

Peripheral insulin resistance (IR) in subjects with impaired glucose tolerance and type 2 diabetes (T2D) triggers IR in the brain (Chow et al., 2019) that contributes to Aβ, pTau phosphorylation (pTau), oxidative stress, advanced glycation end products, and apoptosis (Rorbach-Dolata & Piwowar, 2019), thus redefining AD as a disturbance of insulin singnaling in the brain (Biessels, Kappelle, & Utrecht Diabetic Encephalopathy Study, 2005). Aβ, pTau, and resultant inflammatory mediators stimulate pro-inflammatory serine/threonine protein kinases (e.g., extracellular signal-regulated kinase [ERK], and stress-activated protein kinases p38 and c-Jun N-terminal kinase [JNK]) and transcription pathways (e.g., NFκB). Inflammatory activation of these kinases subverts insulin signaling through its cellular receptor both in the periphery and in the brain, leading to serine-phosphorylated insulin receptor substrates (IRS1/2) that inhibit insulin signals to downstream targets (Berlanga-Acosta et al., 2020; Shaughness, Acs, Brabazon, Hockenbury, & Byrnes, 2020; Q. Zhang et al., 2018). IR results in decreased glucose utilization and complex metabolic dysregulation, leading to neuron death.

Bezisterim is an oral, blood-brain barrier–permeable, anti-inflammatory, insulin-sensitizing (Ahlem et al., 2011) analog of the neurosteroid androst-5-ene-3β,7β,17β-triol (beta-AET) (Ahlem et al., 2011) with an attractive safety profile to date (C. L. Reading, Flores-Riveros, Stickney, & Frincke, 2013; C. L. Reading, Stickney, et al., 2013; C. L. Reading et al., 2025). Bezisterim binds ERK and ribosomal protein S6 kinase alpha-3 (Rsp6ka3) (C. L. Reading, Frincke, & White, 2012) and inhibits NFκB (M. Lu et al., 2010; T. Wang et al., 2010). We previously reported an exploratory analysis of potentially beneficial differences in neurological and metabolic measures, as well as DNA methylation measures between bezisterim and placebo in mild to moderate AD, in addition to correlations between these measures and decreased age acceleration for the SkinBloodAge, Hannam, GrimAge, PhenoAge, and InflammAge clocks (C. L. Reading et al., 2025).

These findings led us to further investigate the possibility that bezisterim-induced changes in DNA methylation of certain genes might be related to clinical benefit. We chose to investigate genes that showed a significant difference in average differential promoter methylation (DPM) - genes that might be associated with changes in expression- following treatment with bezisterim compared to placebo and to investigate those and related genes, for potentially beneficial effects in aging and AD. We investigated potentially beneficial changes in genes shared with genes known to impact aging and disease of aging and documented published relationships for further exploration. We also explored genes with associations to metabolic inflammation, e.g., AD-nominated targets, aging, cognition, diabetes, obesity, lipid metabolism, glycolysis, M1 polarization, inflammatory kinase cascades, and dysregulated phosphoproteins. Besides DNA methylation, we also investigated genes related to epigenetic changes through chromatin reorganization (i.e., histone modifications) (Lin et al., 2022) and alterations in TF activity related to control of inflammatory gene expression. Additionally, we documented publications relating to these gene activities and examined correlations between DPM genes and clinical measures.

2. Materials and Methods

2.1. DNA methylation assessment

Whole blood specimens were collected at baseline and follow-up, and shipped on cold chain to TruDiagnostic (Lexington, KY) for DNA extraction and methylation profiling. Genomic DNA (500 ng) was bisulfite-converted using the EZ DNA Methylation kit (Zymo Research) per manufacturer instructions. Bisulfite-converted DNA was randomized across chips/plates and hybridized to Illumina Infinium Methylation arrays (primarily EPIC v2.0; within-array–type analyses were performed when multiple array types were present). Post-hybridization processing (amplification, staining, washing) and imaging were performed on an Illumina iScan, and raw fluorescence intensities were exported as IDAT files using an encrypted binary file format. When possible, longitudinal samples from the same participant were co-processed on the same chip to minimize batch effects.

2.2. DNA methylation (DNAm) data preprocessing (minfi-based)

R raw IDATs were read with minfi (read.metharray) and assigned the EPIC v2.0 custom manifest (IlluminaHumanMethylationEPICv2; 20a1.hg38) (Aryee et al., 2014). A per-run quality control report was generated. Probe-level detection *P* values were computed from methylated + unmethylated signals (detectionP, type = "m+u"). Samples with mean detection *P* > 0.05 were flagged a priori for exclusion; in this dataset no samples were removed, and 5'-cytosine-phosphate-guanine-3' (CpG)-level filtering at the same threshold was evaluated but not applied. Background correction and dye-bias normalization used Noob (preprocessNoob, dyeMethod = "single"), after which beta values were exported (Fortin, Triche, & Hansen, 2017). Because the dataset used an EPIC v2.0 custom design, probe intensities were collapsed to EPIC v2.0 pfx-level targets to harmonize duplicated probe families. For legacy models requiring HM450/EPIC v1.0 CpGs, missing sites were augmented using array- and tissue-specific medians from sesame's imputation defaults (EPIC.imputationDefault, Blood), ensuring coverage of required loci across methods. The resulting normalized beta matrix and the corresponding RGChannelSet were saved as RDS files for reproducibility.

2.3. Deriving estimates of epigenetic clocks and methylation-based metrics

Epigenetic ages and related methylation metrics were computed from the cleaned beta matrix using validated implementations or author-provided code. Canonical clocks (Horvath multi-tissue (Horvath, 2013), Horvath skin-and-blood (Horvath et al., 2018), Hannum (Hannum et al., 2013), PhenoAge, GrimAge (components and composite) (A. T. Lu et al., 2019), and DNAmTL (A. T. Lu et al., 2019) were estimated; where applicable, principal-component (PC) implementations were used to enhance reliability (Higgins-Chen et al., 2022). DunedinPACE was projected using the authors' code (Belsky et al., 2022); epiTOC2 outputs (TNSC/TNSC2, pcgtAge, solo-WCGW HypoClock) were derived from the published CpG sets (Teschendorff, 2020). System-specific aging (SystemsAge) was quantified by projecting blood DNAm PCs onto organ-system axes (blood, brain, inflammation, heart, hormone, immune, kidney, liver, metabolic, lung, musculoskeletal), scaling predictions to years, and converting to age-adjusted residuals using reference-cohort parameters before re-centering to absolute system ages (Sehgal et al., 2025). Fitness-related estimators (DNAmGrip, DNAmGait, DNAmVO☐max) and DNAmFitAge were computed per their specifications (McGreevy et al., 2023). Additional causal/stochastic and other clocks (AdaptAge, CausAge, DamAge (Ying et al., 2024); stochastic

Horvath/Hannum/PhenoAge/Zhang (Tong et al., 2024); IntrinClock with adult-age back-transformation (Tomusiak et al., 2024); Marioni cAge with linear/log models and squared terms for under-20 predictions (Bernabeu et al., 2023); RetroClock v1/v2 (Ndhlovu et al., 2024) were generated from published coefficient tables or locked models.

Epigenetic biomarker proxies (EBPs) – penalized methylation scores predicting circulating proteins (Olink/SEER), metabolites (Metabolon), and clinical traits – were applied using locked weights and intercepts (Carreras-Gallo et al., 2024); when an EBP required loci absent from the working array, values were filled using the same reference-median imputation described above and then refined with K-nearest-neighbor imputation where necessary. The OMICmAge combined CpGs, immune fractions (from EpiDISH 12-cell RPC deconvolution), EBPs, age, and sex within a penalized regression model, and was scaled to calendar years using the model's parameters (Carreras-Gallo et al., 2024). Unless otherwise specified by the original method, scores were computed on beta values. For downstream analyses, epigenetic metrics (e.g., clocks, telomere proxy, immune deconvolution, EBPs, EpiScores) were age- and covariate-adjusted using linear models that included chronological age, sex, and cell-type fractions; SystemsAge followed its published calibration procedure. All scripts were written in R (key packages: minfi, sesame, EpiDISH, ENmix, DunedinPACE, glmnet, data.table, tidyverse), and model resources (PC-clock rotations, SystemsAge coefficients, EBP weights) were loaded from locked RData/CSV files. Final outputs included per-participant tables of clock values, cell-type estimates and ratios, EBPs, SystemsAge domains, and ancillary predictors (e.g., DNAmFEV1) for statistical testing.

2.4. Analysis of changes in promoter methylation between bezisterim and placebo

DNAm was assessed using the Illumina Infinium Methylation EPIC v2.0 BeadChip, applied to DNA samples collected at study completion. Raw array data were preprocessed according to our previously described method (C. L. Reading et al., 2025), which was included in sample collection, processing, and statistical analysis section. Of the samples processed, 33 met quality control criteria and were retained for downstream analysis.

Promoter region methylation levels were extracted, and the mean β value across CpG sites in promoter regions was calculated for each CpG. Average differences in promoter methylation between the bezisterim group (N = 17) and placebo group (N = 16) were computed

for each gene based on UCSC_RefGene_Name annotations. Statistical significance of these differences was evaluated using parametric testing, and *P* values were corrected for multiple testing by the Benjamini–Hochberg false discovery rate (FDR) procedure, with a significance threshold of FDR < 0.05.

Genes were further filtered to retain only those with an absolute mean methylation difference ≥ 5% (rounded to the nearest integer). These genes were designated as DPM genes and subjected to subsequent downstream analyses.

2.5. Genes associated with epigenetic age acceleration (EAA) in biological clocks

The genes associated with CpGs were identified for clocks with significant differences in EAA, and these genes were cross-referenced for DPM matches and termed "DPM clock genes."

2.6. Artificial intelligence (AI) disclosure

Each gene in Table S2a (Supplemental File 1) was searched in Chrome using AI mode separately for the following traits: "Alzheimer," "Nominated target," "Microglial neuroinflammation," "Inflammation," "Cognition," "Diabetes," "Obesity," "M1 polarization," "Glycolysis," "Kinase cascades," "Phosphoprotein," "Lipids," "Chromatin remodeling," and "Transcription factor." Potentially beneficial changes in genes were identified and curated from the published data, with specific links provided in Supplemental File 3.

3. Results

3.1. Epigenetic clocks

Figure 1 provides evidence that bezisterim-treated subjects had significantly decreased EAA in 12 aging clocks (PC Horvath2., PC Hannum. PC GrimAge., DamAge., IntrinClock, Stochastic Zhang, Stochastic Horvath1, Stochastic PhenoAge, RetroClock. , RetroClockV2, SystemsAge, and Heart), in addition to the previously reported 5 age acceleration clocks (SkinBloodAge, Hannam, GrimAge, PhenoAge, and InflammAge) (C. L. Reading et al., 2025). Significant trends were observed that indicated age deceleration, i.e., negative age acceleration in each of the 12 clocks for bezisterim subjects, while the placebo subjects showed positive age acceleration for each.

3.2 Gene investigations

Since we previously reported potentially beneficial changes in age deceleration, clinical assessments, and metabolic and inflammatory biomarkers with bezisterim (C. L. Reading et al., 2025), we searched for DPM genes whose differential expression might be contributing to these changes. Supplemental File 1, Table S1 lists the various activity parameters investigated for potentially beneficial DPM for genes showing significant bezisterim differences compared to placebo subjects. In addition to genes with differential CpG methylation associated with deceleration of epigenetic aging clocks, we investigated genes with significant DPM for potentially beneficial effects in metabolic inflammation parameters associated with neurodegeneration, and for epigenetic chromatin remodeling and TF activity. Of 2,154 genes that met the criteria, 2136 had increased DPM and only 18 had decreased DPM. The sources for our investigations are listed in Supplemental File 1, Table S1.

3.3. Differences in DNA promoter methylation

Figure 2 shows volcano plots for the differences in DPM between bezisterim and placebo subjects following 7 months of treatment. Figure 2A displays the differences for the 2,154 DPM. We investigated the average promoter CpG methylation beta values as a surrogate for likely altered expression, Details for the DPM genes in Figure 2 are displayed in Table 1, including the number of methylated CpGs in the promoter, percentage of DPM, FDR-adjusted P values, descriptions of their activities, and references. The top five potentially beneficial DPM genes with significant FDR-adjusted $P < 0.001$ are identified in Figure 2A. Their increased DPM suggests potentially decreased expression.

Additional potentially beneficial DPM genes of significance (441 of the total 448) in the region of FDR-adjusted $P > 0.001$ and $P < 0.05$ are displayed in Figure 2B. Genes with 5% or greater DPM are shown in red (potential decreased expression); those with –5% or less DPM are shown in green (potential increased expression). Of the 448 potentially beneficial DPM genes, 433 had significantly increased DPM, but only 15 had significantly decreased DPM. For the 433 genes with significantly increased DPM, potentially beneficial changes Figure 2B) are associated with presumed decreased expression. Only the top 14 gene IDs are shown in the figure for increased DPM (red genes).

For 15 of the 18 genes with significantly decreased DPM, potentially beneficial changes are associated with presumed increased expression based on their known functions as described in Figure 2B.

Based on our published findings of correlations between age deceleration and potential improvements in neurological and functional clinical assessments, as well as metabolic inflammatory measures with bezisterim compared to placebo (C. L. Reading et al., 2025), we investigated epigenetic age deceleration genes for potentially beneficial differences in bezisterim vs placebo for DNA promoter methylation on metabolic inflammation activities.

Figure 3 associates age deceleration clock genes with other published parameters associated with AD, aging, and diseases of aging. Red circles in Figure 3 indicate potentially beneficial differences in genes with increased DPM and known associations to inflammation, gray circles indicate potentially beneficial differences in genes with increased DPM and no identified association to inflammation, and green circles indicate potentially beneficial differences in genes with decreased DPM. Table 2 lists the relationship of genes to inflammation, and the number of shared associations. There were 45 genes identified from significant CpGs in EAA clocks with significant bezisterim-associated age deceleration. Of these, 39 (87%) were associated with inflammation. Overall, there were 249 potentially beneficial associations of bezisterim DPM with diseases of metabolic inflammation and aging for the identified clock genes.

Potential bezisterim benefits were associated with DPM genes with reported plasma concentrations in AD, Parkinson's Disease (PD) and frontotemporal dementia (FTD) (Ali et al., 2025) and with reported AD microglial transcript levels (Kosoy et al., 2025) Elevations in plasma concentrations of eighteen of these were significantly associated with AD, PD and FTD (Ali et al., 2025), and showed significantly increased DPM with bezisterim. One DPM gene with reported decreases plasma concentration with AD and PD (*SP140*) was significantly associated with decreased DPM in bezisterim subjects (Ali et al., 2025). In addition, increased *EFNA4* microglial transcripts were significantly associated with increased AD dementia (Kosoy et al., 2025), but *EFNA4* DPM was significantly decreased with bezisterim. Similarly, increased SOAT1 microglial transcripts were significantly associated with increased Braak pathology score (Kosoy et al., 2025), but *SOAT1* DPM was significantly increased with bezisterim. Conversely, decreased *UBE2C* microglial transcripts were significantly associated with both AD dementia

and Braak pathology score (Kosoy et al., 2025), and *UBE2C* DPM was significantly decreased with bezisterim.

There were also interesting findings for transcriptional regulation. There were seven clock EAA genes that were identified as TFs with potentially beneficial DPM increases with bezisterim. Three of these TFs (*RUNX2*, *STAT3*, and *TCF12*) were significantly associated with transcription of 43 of the 45 shared genes, suggesting that increases in DNAm of TF expression might compound the effects of decreased expression of target genes with increased DPM associated with bezisterim.

We further explored associations among metabolic inflammation, aging, and AD in the bezisterim DPM genes. Figure 4 indicates sharing of genes among the risk factors in Table S1 (Supplemental File 1). We discovered a total of 448 (including the 45 clock genes) shared genes, 355 (79%) of which were associated with inflammation. There were a total of 1,671 shared risks with potentially beneficial bezisterim DPM. Similar to the findings in the shared clock gene matrix, shared potentially beneficial differential promoter methylation PBDPM genes included 189 related to cognition, 156 to T2D and IR, 148 to obesity, 146 to M1 polarization, 143 to inflammatory kinase cascade genes, 120 to lipid dysregulation, 90 to glycolysis and Warburg effect genes, 76 to dysregulated phosphoproteins, 37 to nominated aging and AD risk targets, 75 to chromatin remodeling genes, and 78 to TFs. The inflammatory kinase cascades are interesting, as increasing inflammatory kinase DNA methylation might compound the effect through sequential phosphorylation in signaling cascades (e.g., NFκB, mitogen-activated protein kinase [MAPK], p38, JNK), especially when sequential kinases also have increased DNA promoter methylation.

There was evidence of overlaps in shared genes with neurodegenerative diseases. In AD, PD and FTD plasma, 150 PBDPM genes had significantly increased plasma concentrations (Ali et al., 2025) but significantly increased DPM with bezisterim, and one (UBE2C) with significantly decreased AD and PD plasma concentrations had decreased DPM with bezisterim. Of these 151 genes, 106 were associated with potential improvements in AD plasma levels, 62 were associated with PD and 34 were associated with FTD (Tables S2b, S24, S25, S26). There were also 71 genes with significantly increased microglial transcripts for AD dementia or Braak pathology score (Kosoy et al., 2025) but significantly increased DPM with bezisterim.

The potential of TF-compounding effects on gene expression was also seen in the larger matrix. A total of 438 of the 448 PBDPM genes were significantly associated with transcription by 39 of the 78 identified PBDPM TFs. Supplemental File 1 contains a master table (Table S2a) and master figure (Table S2b), which also contain the gene name and the DNA methylation information for each gene. Supplemental File 2 contains 31 supplemental tables with individual clock or trait sharing with all of the other parameters (Tables S3-S29), and the TF results for ChEA 2022 and ENCODE 2015 for all shared genes (Tables S30 and S31) and shared clock genes (Tables S32 and S33).

We further investigated the relationships between the sum of promoter methylation for each of the 448 genes for correlations with clinical measures from the prior study. We examined correlations with the 31 parameters in Table S34 (Supplemental File 4).

3.4 Bezisterim FDR gene sum of promoter methylation correlations with clinical measures

As shown in Table S35 (Supplemental File 4), lower Alzheimer's Disease Composite Score (ADCOMS), Clinical Dementia Rating-Sum of Boxes (CDR-SB), Clinical Global Impression of Change (CGIC), cholesterol, ADAS-Cog12, Global Statistical Test (GST), triglycerides, waist-to-hip ratio (WHR), and weight (all improvements) in bezisterim subjects were significantly associated with increased promoter methylation of 47 genes (all negative correlations).

Higher Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scores (improvement) in bezisterim subjects were significantly associated with increased promoter methylation of 25 genes (positive correlations). The majority (66) of these were associated with neurologic (ADCOMS=7; ADCS-ADL=25; CDR-SB=10; CGIC=1; GST=10) and metabolic (cholesterol=6; triglycerides=3; WHR=1; weight=3) measures.

Lower C1q (improvement) in bezisterim subjects was significantly correlated with a decreased *SLC28A2-AS1* promoter methylation (positive correlation).

LIME1 associations were inconsistent. Although an increase in *LIME1* promoter methylation was correlated with decreased triglycerides, it was also associated with increased ADAS-ADAS-Cog12 and glucose, and decreased Mini-Mental State Exam (MMSE) scores. After reviewing its activity, it appears to be associated with immune regulation, but not inflammation, and its DPM is not uniformly "potentially beneficial."

Twelve genes had multiple correlations with clinical measures: *CDK2AP1=3*, *DGKZ=4*, *IL6R=5*, *JDP2=4*, *KLF7=5*, *LIME1=4*, *NEU1=3*, *NRBP1=4*, *P2RX1=4*, *SAT2=4*, *TGFBR2=2*, and *TGIF1=4* (Supplemental File 4, Table S37).

There were significant differences (Z score P) between 48 of the significant bezisterim Pearson R values for correlations of the same gene and measure between bezisterim and placebo (Supplemental File 4, Table S39). Examples of the bezisterim PBDPM gene correlations with neurologic measures are shown in Figure 5A.

3.5 Placebo FDR gene sum of promoter methylation correlations with clinical measures

As shown in Table S36 (Supplemental File 4), higher ADCOMS, ADAS-Cog12, GST, and glial fibrillary acidic protein (GFAP) in placebo subjects were significantly negatively correlated with total promoter methylation. Since the correlated genes all showed decreased total promoter methylation compared to bezisterim, these data represent relative AD decline compared to bezisterim. GFAP was uncorrelated in bezisterim subjects.

In placebo subjects, there was one potentially beneficial correlation. ADCS-ADL scores were significantly negatively correlated with *LEPR* promoter methylation sum. *LEPR* was uncorrelated with neurologic assessments in bezisterim subjects. The difference between potentially significant promoter methylation and neurologic assessments in bezisterim and placebo subjects was significant (54/72 vs 1/13, Fisher Exact Test $P = 6.6e-6$).

Examples of significant placebo DMP correlations are shown in Figure 5B. glial fibrillary acidic protein (GFAP) risk was associated with 3 genes (*GPD2, IRF3*, and *P2RX*1), and 1 gene (*NINJ2*) was correlated with 3 neurological assessments (ADCOMS, ADAS-Cog12 and GST). Since the placebo has decreased promotor methylation, the negative correlations for placebo reflect potential increased risk.

Systolic blood pressure in placebo subjects was significantly positively correlated with promoter methylation of six genes (*CSNK1D*, *CTSL*, *ETV1*, *MTHFR*, *SMARCD2*, and *TUBA4A*). Systolic blood pressure was uncorrelated in bezisterim subjects. There was an apparent relative increase in total promoter methylation of each of the six genes at lower systolic blood pressures (Figure 6).

As shown in Supplemental File 4, Table S38, *NINJ2* was correlated with ADCOMS, ADAS-Cog12, and GST. There were significant differences (Z score P) between two of the

significant placebo Pearson R values for correlations of the same gene and measure between bezisterim and placebo (Supplemental File 4, Table S40). There were more significant bezisterim correlations (72) compared to placebo (13). The difference was significant (Fisher Exact test $P = 5.5e-12$).

There were no significant differences in the frequency of shared genes for any of the bezisterim correlates (Supplemental File 4, Table S41), placebo correlates (Supplemental File 4, Table S42), or overall DPM genes (Supplemental File 1, Table S2a). Of the 38 bezisterim-correlated genes, 84% were associated with inflammation; 10 of these were shared with reported increased AD concentrations, and four were shared with reported increased microglial transcripts. For placebo-correlated genes, 100% were associated with inflammation (Supplemental File 4: Tables S41 and S42).

4. Discussion

4.1 Epigenetic clocks

Epigenetic aging clocks have provided insight into risk factors associated with diseases of aging (Horvath, 2015). The insight is limited, however, due to the uncertainty of the effect of methylation of a single CpG that might either increase or decrease expression depending on its location in or around a given gene. For the current analysis, the genes associated with significant bezisterim-associated age deceleration clock CpGs were identified. These genes were cross-referenced with bezisterim-associated DPM genes having significant average CpG methylation differences based on multiple promoter methylation sites. This DPM analysis may provide higher probability of regulation of expression.

We identified 45 EAA clock genes with significant potentially beneficial DPM. For the significant age deceleration of the PC Horvath EAA clock (Figure 1), there were nine DPM genes identified that were all associated with inflammation (Figure 3). Previously, we found correlations between the SkinBloodAge EAA scores (Horvath et al., 2018) at study completion for bezisterim subjects and neurologic assessments (C. Y. Reading, J.; Schmunk, L.; Martin-Herranz, D.; Ahlem, C.; Markham, P.; O'Quinn, S.; Palumbo, J., 2025) We found significant negative correlations for GST, CDR-SB, ADCOMS, and ADAS-Cog12, and a positive correlation for ADCS-ADL. There were no significant correlations for placebo subjects. In this study, we found significant correlations of bezisterim potentially beneficial DPM EAA clock

genes with clinical measures in four EAA clock genes (Table S41). NRBP1 from the DamAge.EAA clock was correlated with ADL, CDR SB, GST, and ADCOMS., *NRBP1* from the DamAge EAA clock was correlated with ADCS-ADL, CDR-SB, GST, and ADCOMS. *MJD6* from the IntrinClock EAA was correlated with ADCS-ADL. *DGKZ* from the StocPhenoAge EAA was correlated with ADCS-ADL, CDR-SB, GST, and ADCOMS. IL12RB1 was correlated to triglycerides. There were no significant correlations between placebo DPM clock genes and neurologic assessments. The gene CSNK1D was represented in 3 EAA clocks (IntrinClock.EAA, StocZhang.EAA and StocHorvath.EAA), and was correlated with systolic blood pressure, which may be a risk for decreased cerebral perfusion.

4.2 Investigations of identified potentially beneficial DPM genes

Although increased 10-fold in gene numbers, sharing data for all potentially beneficial DPM in Figure 4 is similar to that for potentially beneficial clock genes in Figure 3. The overall patterns show sharing of associations with inflammatory, metabolic, and transcriptional dysregulation. Genes with relevant activities for aging and AD due to genetic mutations and single nucleotide polymorphisms,(SNPs) were not included in the shared gene analysis, since it is unlikely they would be represented at a level high enough to impact the conclusions from small clinical sample numbers.

4.3 Differences in promoter methylation

FDR-adjusted $P < 0.05$ with significant DPM was identified in 2,154 of 11,322 genes (19%). Potentially beneficial effects of DPM were identified for the top five genes, and for 433 of the genes with increased DPM and 15 genes with decreased DPM (Figure 2). The significance of these findings supports a bona fide activity of bezisterim to enrich AD subjects' DPM of genes in a potentially beneficial manner. Identified potentially beneficial DPM genes represent 2,154/11,322 (19% of all DPM) with FDR $P < 0.05$. For an unrelated gene set (SOMAscan and OLINK AD genes [35023833]), there were 0/133 significant DPM genes. The difference is significant (Fisher Exact Test $P = 8.4e-11$).

The data from Figures 3 and 4 and Table 1 suggest broad functional associations between the DPM of specific genes and AD/aging risks, potentially identifying molecular changes associated with bezisterim-associated systems biology effects. Inflammation risk was the major

shared trait and may represent the teleologic basis for the associations. Evolutionary control of responses to pathogens has selected for regulatory responses to eliminate the pathogen, followed by termination of the response, with resolution and repair of damage associated with the process. This regulation is a double-edged sword, since metabolic diseases, including T2D and obesity, are associated with overnutrition, which is only recently epidemic, even as increased longevity allows for age-associated neurologic diseases such as AD and PD, conditions which are also evolutionarily recent. These conditions create DAMPs (e.g., glycosylated proteins, prion-like protein aggregates) that trigger DAM, but resolution of the process is lacking, since inflammatory responses increase, rather than eliminate, the DAMPs. Based on the potentially beneficial DPM associations evident with genes associated with decreased M1 microglial and macrophage responses, and the requisite Warburg glycolysis effect, we can hypothesize that bezisterim may have an effect on homeostatic restoration in the face of metabolic and protein aggregation inflammatory responses. Bezisterim decreased macrophage inflammatory responses, kinase cascades, and IR in diabetes models (M. Lu et al., 2010; T. Wang et al., 2010). In subjects with impaired glucose tolerance and obesity, bezisterim treatment leads to increased insulin-stimulated glucose disposal, increased HDL cholesterol, decreased C-reactive protein (CRP), and decreased IR (C. L. Reading, Stickney, et al., 2013) while improving insulin sensitivity, metabolic dysregulation, and hemoglobin-A1c (HbA1c) (C. L. Reading, Flores-Riveros, et al., 2013). In AD, bezisterim decreased glucose, cholesterol, and monocyte chemoattractant protein 1, and increased homeostatic model 2 insulin sensitivity and beta cell function with alterations in the monocyte methylome (C. Y. Reading, J.; Schmunk, L.; Martin-Herranz, D.; Ahlem, C.; Markham, P.; O'Quinn, S.; Palumbo, J., 2025). Data in Figures 3 and 4 and Table 1 for inflammation, kinase cascades, M1 polarization, and glycolysis suggest that bezisterim may alter the polarization of macrophages and microglia, inducing a shift from an M1 pro-inflammatory state to an M2 restorative state. We reported that bezisterim appeared to alter the monocyte methylome in AD subjects. (C. Y. Reading, J.; Schmunk, L.; Martin-Herranz, D.; Ahlem, C.; Markham, P.; O'Quinn, S.; Palumbo, J., 2025)

After inflammation, the second most prevalent gene sharing was with cognition risks. There were 189 potentially beneficial DPM genes associated with cognition (Figure 4). We previously found that bezisterim subjects' neurological assessments in the AD study were

significantly correlated with age deceleration, measured by the SkinBloodAge clock (C. Reading, 2024).

Placebo subjects did show significant positive correlations between AD biomarkers and neurological assessments (C. Reading, 2024) GFAP, pTau and neurofilament light chain (NfL) were significantly positively correlated with GST and CDR-SB; GFAP and pTau were significantly positively correlated with ADCOMS and ADAS-Cog12, and significantly negatively correlated with the MMSE, for which decreased scores are associated with cognitive decline; and the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC), for which increased scores are associated with cognitive decline, were positively correlated with pTau and NfL. In contrast, for bezisterim subjects, GFAP was significantly negatively correlated with MMSE, and NfL was negatively correlated with ADCS-ADL.

For inflammation, CRP was significantly negatively correlated with MMSE in bezisterim subjects, indicating that decreased CRP was associated with improvement; however, for placebo subjects, CRP was negatively correlated with ADAS-Cog12, indicating that inflammation was associated with cognitive decline. For bezisterim subjects, cholesterol was positively correlated with GST and ADAS-Cog12, suggesting the decrease seen in bezisterim subjects was associated with the improvements in GST and ADAS-Cog12.

The prior findings support the proposition that bezisterim may be altering the expression of genes impacting AD and cognition, inflammation, and dysregulated lipid metabolism. In this study, there were potentially beneficial changes of approximately 8% overall in 433 genes with increased DPM, and –11% overall in 15 genes with decreased DPM. This number may be an underestimation of the overall effect for four reasons: First, kinase cascades involved in signal transduction involve sequential phosphorylation of several kinases and targets (e.g., MAPK4, MAPK3, MAPK2, and MAPK, followed by phosphoprotein targets, including TFs), which may lead to compounding effects on the targets and TFs. Second, as shown in Figures 3 and 4, TFs with DPM are involved in the transcription of genes with DPM, again leading to compounding effects. Third, chromatin-remodeling genes with DPM alter access to the TFs with multiple DPM. Finally, transcription factors work in concert, suggesting that for multiple DPM gene transcription factors with potentially decreased expression may have a compounding effect on transcription at a promoter with multiple TF sites, with further impact if the site is for a DPM gene..

Systems biology is fraught with complexity, and many of the citations for inflammatory mediators warn of the complex dependency of a pro- or anti-inflammatory effect. In addition to learning more about mechanisms of inflammatory processes in AD and aging, our goal is to define biomarkers of response to bezisterim. Since there were potentially beneficial responses in the AD study (C. L. Reading et al., 2025), we have focused on potentially beneficial DPM genes. In the absence of reported clinical serious adverse events to date, we have not explored potentially damaging DPM, and the definition would be tenuous, because the context following bezisterim treatment is clearly different than placebo. In fact, the modulation of DPM may be involved in the safety profile, since an 8-11% increase or decrease in DPM has limited impact compared to complete inhibition, mutation, or knockout of a gene. Also, the number of nominated target genes in Figures 3 and 4 are smaller than other parameters, possibly since thorough inhibition of most genes can result in serious effects or diseases.

Data for all potentially beneficial DPM in Figure 4 are similar to that for potentially beneficial clock genes in Figure 3. The overall patterns show sharing of associations with inflammatory, metabolic, and transcriptional dysregulation. For available plasma levels of potentially beneficial clock DPM genes, 10 of 45 gene products were reported to be significantly increased in AD plasma, but had higher DPM with bezisterim, likely associated with decreased expression. For the overall shared genes, 105 of 433 potentially beneficial DPM genes with increased methylation were reportedly significantly increased in plasma, and one of 15 potentially beneficial DPM genes with decreased methylation was reportedly significantly decreased in plasma.

Although shared genes were based on bezisterim-associated DNA promoter methylation of genes, due to alternative splicing and post-translational modifications, proteoforms of the approximately 20,000 human protein-coding genes may exceed 10 times that number (Aebersold et al., 2018). Information regarding the extent of functional changes due to specific splicing alterations in AD is scarce (Koch, 2018). For instance, splice variants of *ADIPOR2* are associated with decreased amyloid; *FDPS* are associated with increased neuritic plaques; *LPCAT4* is associated with increased tangles; *PFPK* increases neuritic plaques, tangles, and amyloid, SOD2 , and TMEM14C increased tangles. These data suggest that splice variants may have opposite effects from the normal message or protein on AD biomarkers, and thus also on risk factors.

4.4 FDR gene sum of promoter methylation correlations

The sum of promoter CpG methylation for each of the potentially beneficial DPM genes was analyzed for correlations with clinical measures from the previous clinical study (Reading, et al., 2025). With bezisterim, we found evidence for 38 significant associations of potentially beneficial DPM of genes that correlated with neurologic assessments and metabolic measures.

For placebo subjects, there were significantly fewer correlations than with bezisterim subjects, and only three for neurologic assessments. ADCOMS and ADAS-Cog12 correlations indicated that decreased DPM compared with bezisterim related to relative decline.

The significant positive placebo correlations of systolic blood pressure reveal that in AD, the correlated genes may contribute to decreased CNS perfusion (i.e., lower methylation of *CSNK1D*, *CTSL*, *ETV1*, *MTHFR*, *SMARCD2*, and *TUBA4A* may result in lower systolic pressure and CNS perfusion). In subjects treated with bezisterim, this correlation was not significant. Bezisterim treatment was not associated with hypertension, but there was an apparent relative increase in total promoter methylation of each of the six genes at lower systolic blood pressures. This change suggests increased CNS perfusion in bezisterim subjects.

5. Conclusions

There is evidence that bezisterim may modulate epigenetic effects in a pattern associated with inflammatory responses that are related to diseases of aging. Bezisterim decreased epigenetic age acceleration in a total of 17 biological aging clocks that have been shown to be associated with aging in general. In particular, bezisterim decreased EAA in three stochastic clocks, which are based on changes in aging, rather than clocks such as the DamAge and GrimAge clocks that are associated with effects of diseases of aging. Based on epigenetic age acceleration clocks, and evidence of correlations between potential gene expression differences and clinical responses for neurological and metabolic measures, it is tempting to speculate that bezisterim may increase healthspan in general. The specifics of biomarkers that can be derived from this study await replication in a larger AD population. We are currently collecting DNA methylation data for bezisterim trials in PD (NCT06757010) and in Long Covid (NCT06847191), with the possibility of understanding the generalizability of these findings in other neurodegeneration settings.

Acknowledgements

Editorial support was provided by *p*-value communications and funded by BioVie Inc.

Funding Statement

This study was funded by BioVie Inc.

Conflict(s) of Interest Statement

During the conduct of the study, CR, JY, CA, PM, and JP were employed by BioVie Inc, and VBW was employed by TruDiagnostic, Inc. SO'Q is a consultant to BioVie and is affiliated with Perissos, Inc., Wake Forrest, NC.

Ethics Statement

The studies from which the DNA methylation data was obtained involving humans (NCT04669028; https://clinicaltrials.gov/study/NCT04669028?term=NCT04669028&rank=1) received IRB approval from ADVARRA (MOD01862543). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Data Availability Statement

The data that support the findings of this study are available in the main text and supplementary materials of the article.

References

Aebersold, R., Agar, J. N., Amster, I. J., Baker, M. S., Bertozzi, C. R., Boja, E. S., . . . Zhang, B. (2018). How many human proteoforms are there? *Nat Chem Biol, 14*(3), 206-214. doi:10.1038/nchembio.2576

Agora, C. (n.d.). CELF1, CUGBP Elav-like family member 1. Retrieved from https://agora.adknowledgeportal.org/genes/ENSG00000149187

Agora, F. (n.d.). FBXL16, F-box and leucine rich repeat protein 16. Retrieved from https://agora.adknowledgeportal.org/genes/ENSG00000127585

Agora, J. (n.d.). JMJD6, jumonji domain containing 6, arginine demethylase and lysine hydroxylase. Retrieved from https://agora.adknowledgeportal.org/genes/ENSG00000070495

Ahlem, C. N., Kennedy, M. R., Page, T. M., Reading, C. L., White, S. K., McKenzie, J. J., . . . Frincke, J. M. (2011). Studies of the pharmacology of 17alpha-ethynyl-androst-5-ene-3beta,7beta,17beta-triol, a synthetic anti-inflammatory androstene. *Int J Clin Exp Med, 4*(2), 119-135. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21686136

Ahmad, S., Elsherbiny, N. M., Bhatia, K., Elsherbini, A. M., Fulzele, S., & Liou, G. I. (2014). Inhibition of adenosine kinase attenuates inflammation and neurotoxicity in traumatic optic neuropathy. *J Neuroimmunol, 277*(1-2), 96-104. doi:10.1016/j.jneuroim.2014.10.006

Akrioti, E., Karamitros, T., Gkaravelas, P., Kouroupi, G., Matsas, R., & Taoufik, E. (2022). Early Signs of Molecular Defects in iPSC-Derived Neural Stems Cells from Patients with Familial Parkinson's Disease. *Biomolecules, 12*(7). doi:10.3390/biom12070876

Alanazi, F. J., Alruwaili, A. N., Aldhafeeri, N. A., Ballal, S., Sharma, R., Debnath, S., . . . Imran, M. (2025). Pathological interplay of NF-kappaB and M1 macrophages in chronic inflammatory lung diseases. *Pathol Res Pract, 269*, 155903. doi:10.1016/j.prp.2025.155903

Ali, M., Erabadda, B., Chen, Y., Xu, Y., Gong, K., Liu, M., . . . Cruchaga, C. (2025). Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases. *Nat Med, 31*(8), 2567-2577. doi:10.1038/s41591-025-03833-1

An, N., Bassil, K., Al Jowf, G. I., Steinbusch, H. W. M., Rothermel, M., de Nijs, L., & Rutten, B. P. F. (2021). Dual-specificity phosphatases in mental and neurological disorders. *Prog Neurobiol, 198*, 101906. doi:10.1016/j.pneurobio.2020.101906

Anderegg, M. A., Gyimesi, G., Ho, T. M., Hediger, M. A., & Fuster, D. G. (2022). The Less Well-Known Little Brothers: The SLC9B/NHA Sodium Proton Exchanger Subfamily-Structure, Function, Regulation and Potential Drug-Target Approaches. *Front Physiol, 13*, 898508. doi:10.3389/fphys.2022.898508

Aryee, M. J., Jaffe, A. E., Corrada-Bravo, H., Ladd-Acosta, C., Feinberg, A. P., Hansen, K. D., & Irizarry, R. A. (2014). Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics, 30*(10), 1363-1369. doi:10.1093/bioinformatics/btu049

Avram, S., Shaposhnikov, S., Buiu, C., & Mernea, M. (2014). Chondroitin sulfate proteoglycans: structure-function relationship with implication in neural development and brain disorders. *Biomed Res Int, 2014*, 642798. doi:10.1155/2014/642798

Aykac, A., & Sehirli, A. O. (2020). The Role of the SLC Transporters Protein in the Neurodegenerative Disorders. *Clin Psychopharmacol Neurosci, 18*(2), 174-187. doi:10.9758/cpn.2020.18.2.174

B3GALT4. (2025). B3GALT4, beta-1,3-galactosyltransferase 4. . Retrieved from
https://www.ncbi.nlm.nih.gov/gene/8705

Bahl, S., & Seto, E. (2021). Regulation of histone deacetylase activities and functions by phosphorylation and its physiological relevance. *Cell Mol Life Sci, 78*(2), 427-445. doi:10.1007/s00018-020-03599-4

Bai, P., Mondal, P., Liu, Y., Gomm, A., Suen, C., Yang, L., . . . Wang, C. (2025). HDAC11 displays neuropathological alterations and offers as a novel drug target for Alzheimer's disease. *Alzheimers Dement, 21*(3), e14616. doi:10.1002/alz.14616

Bastie, C. C., Zong, H., Xu, J., Busa, B., Judex, S., Kurland, I. J., & Pessin, J. E. (2007). Integrative metabolic regulation of peripheral tissue fatty acid oxidation by the SRC kinase family member Fyn. *Cell Metab, 5*(5), 371-381. doi:10.1016/j.cmet.2007.04.005

Begin, S. G., F.; Tchernof, A.; Deshais, Y.; Perusse, L.; Hould, F.S.; Lebel, S.; Marceau, P.; Vohl, M.C. (2016). The rare allele of DGKZ SNP rs10838599 is associated with variability in HDL-cholesterol levels among severely obese patients. *Integr Obesity Diabetes, 2*(2), 219-224. doi:10.15761/IOD.1000148

Belsky, D. W., Caspi, A., Corcoran, D. L., Sugden, K., Poulton, R., Arseneault, L., . . . Moffitt, T. E. (2022). DunedinPACE, a DNA methylation biomarker of the pace of aging. *Elife, 11*. doi:10.7554/eLife.73420

Benziane, B., Borg, M. L., Tom, R. Z., Riedl, I., Massart, J., Bjornholm, M., . . . Zierath, J. R. (2017). DGKzeta deficiency protects against peripheral insulin resistance and improves energy metabolism. *J Lipid Res, 58*(12), 2324-2333. doi:10.1194/jlr.M079723

Berlanga-Acosta, J., Guillen-Nieto, G., Rodriguez-Rodriguez, N., Bringas-Vega, M. L., Garcia-Del-Barco-Herrera, D., Berlanga-Saez, J. O., . . . Valdes-Sosa, P. A. (2020). Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review. *Front Endocrinol (Lausanne), 11*, 560375. doi:10.3389/fendo.2020.560375

Bernabeu, E., McCartney, D. L., Gadd, D. A., Hillary, R. F., Lu, A. T., Murphy, L., . . . Marioni, R. E. (2023). Refining epigenetic prediction of chronological and biological age. *Genome Med, 15*(1), 12. doi:10.1186/s13073-023-01161-y

Bi, L., Ren, Y., Feng, M., Meng, P., Wang, Q., Chen, W., . . . Wang, Y. (2021). HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness. *Cancer Res, 81*(8), 2015-2028. doi:10.1158/0008-5472.CAN-20-3044

Biessels, G. J., Kappelle, L. J., & Utrecht Diabetic Encephalopathy Study, G. (2005). Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? *Biochem Soc Trans, 33*(Pt 5), 1041-1044. doi:10.1042/BST0331041

Boks, M. P., Houtepen, L. C., Xu, Z., He, Y., Ursini, G., Maihofer, A. X., . . . Kahn, R. S. (2018). Genetic vulnerability to DUSP22 promoter hypermethylation is involved in the relation between in utero famine exposure and schizophrenia. *NPJ Schizophr, 4*(1), 16. doi:10.1038/s41537-018-0058-4

Cao, J., Sun, L., Aramsangtienchai, P., Spiegelman, N. A., Zhang, X., Huang, W., . . . Lin, H. (2019). HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2. *Proc Natl Acad Sci U S A, 116*(12), 5487-5492. doi:10.1073/pnas.1815365116

Carreras-Gallo , N., Chen, Q., Balague-Dobon, L., Aparicio, A., Giosan, I. M., Dargham, R., . . . Lasky-Su, J. A. (2024). Leveraging DNA methylation to create Epigenetic Biomarker

Proxies that inform clinical care: A new framework for Precision Medicine. *medRxiv*. doi:10.1101/2024.12.06.24318612

Chang, Y. H., Tseng, Y. H., Wang, J. M., Tsai, Y. S., Liu, X. L., & Huang, H. S. (2024). Phosphorylation of TG-interacting factor 1 at carboxyl-terminal sites in response to insulin regulates adipocyte differentiation. *FEBS Lett, 598*(8), 945-955. doi:10.1002/1873-3468.14849

Chen, C. W., Tsao, N., Zhang, W., & Chang, Z. F. (2020). NME3 Regulates Mitochondria to Reduce ROS-Mediated Genome Instability. *Int J Mol Sci, 21*(14). doi:10.3390/ijms21145048

Chen, H., Xie, C., Chen, Q., & Zhuang, S. (2022). HDAC11, an emerging therapeutic target for metabolic disorders. *Front Endocrinol (Lausanne), 13*, 989305. doi:10.3389/fendo.2022.989305

Chitra, S., Nalini, G., & Rajasekhar, G. (2012). The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases. *Int J Rheum Dis, 15*(3), 249-260. doi:10.1111/j.1756-185X.2012.01737.x

Chow, H. M., Shi, M., Cheng, A., Gao, Y., Chen, G., Song, X., . . . Herrup, K. (2019). Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence. *Nat Neurosci, 22*(11), 1806-1819. doi:10.1038/s41593-019-0505-1

Citron, B. A., Saykally, J. N., Cao, C., Dennis, J. S., Runfeldt, M., & Arendash, G. W. (2015). Transcription factor Sp1 inhibition, memory, and cytokines in a mouse model of Alzheimer's disease. *Am J Neurodegener Dis, 4*(2), 40-48. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26807343

Cunningham, C., & Hennessy, E. (2015). Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. *Alzheimers Res Ther, 7*(1), 33. doi:10.1186/s13195-015-0117-2

Dalmas, E., Toubal, A., Alzaid, F., Blazek, K., Eames, H. L., Lebozec, K., . . . Venteclef, N. (2015). Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity. *Nat Med, 21*(6), 610-618. doi:10.1038/nm.3829

Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., & Amit, I. (2018). Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. *Cell, 173*(5), 1073-1081. doi:10.1016/j.cell.2018.05.003

Deczkowska, A., Matcovitch-Natan, O., Tsitsou-Kampeli, A., Ben-Hamo, S., Dvir-Szternfeld, R., Spinrad, A., . . . Schwartz, M. (2017). Mef2C restrains microglial inflammatory response and is lost in brain ageing in an IFN-I-dependent manner. *Nat Commun, 8*(1), 717. doi:10.1038/s41467-017-00769-0

Deisl, C., Anderegg, M., Albano, G., Luscher, B. P., Cerny, D., Soria, R., . . . Fuster, D. G. (2016). Loss of Sodium/Hydrogen Exchanger NHA2 Exacerbates Obesity- and Aging-Induced Glucose Intolerance in Mice. *PLoS One, 11*(9), e0163568. doi:10.1371/journal.pone.0163568

Elliott, P. J., Zollner, T. M., & Boehncke, W. H. (2003). Proteasome inhibition: a new anti-inflammatory strategy. *J Mol Med (Berl), 81*(4), 235-245. doi:10.1007/s00109-003-0422-2

Erbilgin, A., Seldin, M. M., Wu, X., Mehrabian, M., Zhou, Z., Qi, H., . . . Lusis, A. J. (2018). Transcription Factor Zhx2 Deficiency Reduces Atherosclerosis and Promotes Macrophage Apoptosis in Mice. *Arterioscler Thromb Vasc Biol, 38*(9), 2016-2027. doi:10.1161/ATVBAHA.118.311266

Fang, Y., Lu, Z. H., Liu, B. Z., Li, N., Yang, M. Z., & Wang, P. (2023). IRF5 promotes glycolysis in the progression of hepatocellular carcinoma and is regulated by TRIM35. *J Dig Dis, 24*(8-9), 480-490. doi:10.1111/1751-2980.13218

Fortin, J. P., Triche, T. J., Jr., & Hansen, K. D. (2017). Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi. *Bioinformatics, 33*(4), 558-560. doi:10.1093/bioinformatics/btw691

Fraschilla, I., & Jeffrey, K. L. (2020). The Speckled Protein (SP) Family: Immunity's Chromatin Readers. *Trends Immunol, 41*(7), 572-585. doi:10.1016/j.it.2020.04.007

Friend, C. J. (2023). TGIF1 physiological levels limit ß-cell distress and neonatal diabetes. doi:10.25772/J98Y-M292

Garwain, O., Yerramilli, V. S., Romero, K., & Scarlata, S. (2020). The Galphaq/phospholipase Cbeta signaling system represses tau aggregation. *Cell Signal, 71*, 109620. doi:10.1016/j.cellsig.2020.109620

GDP2. (2024). GPD2, glycerol-3-phosphate dehydrogenase 2. Retrieved from https://omim.org/entry/138430

Ge, C., Tan, J., Dai, X., Kuang, Q., Zhong, S., Lai, L., . . . Xu, M. (2022). Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK. *Nat Commun, 13*(1), 5945. doi:10.1038/s41467-022-33493-5

Guglietti, B., Sivasankar, S., Mustafa, S., Corrigan, F., & Collins-Praino, L. E. (2021). Fyn Kinase Activity and Its Role in Neurodegenerative Disease Pathology: a Potential Universal Target? *Mol Neurobiol, 58*(11), 5986-6005. doi:10.1007/s12035-021-02518-3

Hannum, G., Guinney, J., Zhao, L., Zhang, L., Hughes, G., Sadda, S., . . . Zhang, K. (2013). Genome-wide methylation profiles reveal quantitative views of human aging rates. *Mol Cell, 49*(2), 359-367. doi:10.1016/j.molcel.2012.10.016

Hayashi, H., Kimura, N., Yamaguchi, H., Hasegawa, K., Yokoseki, T., Shibata, M., . . . Yanagisawa, K. (2004). A seed for Alzheimer amyloid in the brain. *J Neurosci, 24*(20), 4894-4902. doi:10.1523/JNEUROSCI.0861-04.2004

He, X., Nie, Y., Zhou, H., Hu, R., Li, Y., He, T., . . . Liu, M. (2021). Structural Insight into the Binding of TGIF1 to SIN3A PAH2 Domain through a C-Terminal Amphipathic Helix. *Int J Mol Sci, 22*(23). doi:10.3390/ijms222312631

Higgins-Chen, A. T., Thrush, K. L., Wang, Y., Minteer, C. J., Kuo, P. L., Wang, M., . . . Levine, M. E. (2022). A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking. *Nat Aging, 2*(7), 644-661. doi:10.1038/s43587-022-00248-2

Hneino, M., Blirando, K., Buard, V., Tarlet, G., Benderitter, M., Hoodless, P., . . . Milliat, F. (2012). The TG-interacting factor TGIF1 regulates stress-induced proinflammatory phenotype of endothelial cells. *J Biol Chem, 287*(46), 38913-38921. doi:10.1074/jbc.M112.388389

Hoff, S., Epting, D., Falk, N., Schroda, S., Braun, D. A., Halbritter, J., . . . Lienkamp, S. S. (2018). The nucleoside-diphosphate kinase NME3 associates with nephronophthisis proteins and is required for ciliary function during renal development. *J Biol Chem, 293*(39), 15243-15255. doi:10.1074/jbc.RA117.000847

Horvath, S. (2013). DNA methylation age of human tissues and cell types. *Genome Biol, 14*(10), R115. doi:10.1186/gb-2013-14-10-r115

Horvath, S. (2015). Erratum to: DNA methylation age of human tissues and cell types. *Genome Biol, 16*(1), 96. doi:10.1186/s13059-015-0649-6

Horvath, S., Oshima, J., Martin, G. M., Lu, A. T., Quach, A., Cohen, H., . . . Raj, K. (2018). Epigenetic clock for skin and blood cells applied to Hutchinson Gilford Progeria Syndrome and ex vivo studies. *Aging (Albany NY), 10*(7), 1758-1775. doi:10.18632/aging.101508

Hou, P., Liu, G., Zhao, Y., Shi, Z., Zheng, Q., Bu, G., . . . Zhang, Y. W. (2015). Role of copper and the copper-related protein CUTA in mediating APP processing and Abeta generation. *Neurobiol Aging, 36*(3), 1310-1315. doi:10.1016/j.neurobiolaging.2014.12.005

Howie, H., Rijal, C. M., & Ressler, K. J. (2019). A review of epigenetic contributions to post-traumatic stress disorder. *Dialogues Clin Neurosci, 21*(4), 417-428. doi:10.31887/DCNS.2019.21.4/kressler

Hu, Y. J., Belaghzal, H., Hsiao, W. Y., Qi, J., Bradner, J. E., Guertin, D. A., . . . Imbalzano, A. N. (2015). Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6. *Nucleic Acids Res, 43*(16), 7790-7804. doi:10.1093/nar/gkv645

Huynh, M. B., Ouidja, M. O., Chantepie, S., Carpentier, G., Maiza, A., Zhang, G., . . . Papy-Garcia, D. (2019). Glycosaminoglycans from Alzheimer's disease hippocampus have altered capacities to bind and regulate growth factors activities and to bind tau. *PLoS One, 14*(1), e0209573. doi:10.1371/journal.pone.0209573

ISOC2. (2025). ISOC2, isochorismatase domain containing 2. Retrieved from https://maayanlab.cloud/Harmonizome/gene/ISOC2#:~:text=Collectively%2C%20these%20studies%20indicate%20that,cycle%20control%20and%20mitochondrial%20integrity,

Kang, J. J., T.: Linli, Z.; Cheng, W.; Guo, S.; Feng, J. (2022). Association between obesity, brain atrophy and accelerated brain aging and their genetic mechanisms. *Health Sciences*. doi:10.1101/2022.12.30.22284052

Karaky, M., Fedetz, M., Potenciano, V., Andres-Leon, E., Codina, A. E., Barrionuevo, C., . . . Matesanz, F. (2018). SP140 regulates the expression of immune-related genes associated with multiple sclerosis and other autoimmune diseases by NF-kappaB inhibition. *Hum Mol Genet, 27*(23), 4012-4023. doi:10.1093/hmg/ddy284

Kim, Y. J., Zhao, Y., Myung, J. K., Yi, J. M., Kim, M. J., & Lee, S. J. (2021). Suppression of breast cancer progression by FBXL16 via oxygen-independent regulation of HIF1alpha stability. *Cell Rep, 37*(8), 109996. doi:10.1016/j.celrep.2021.109996

Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018). Inflammation as a central mechanism in Alzheimer's disease. *Alzheimers Dement (N Y), 4*, 575-590. doi:10.1016/j.trci.2018.06.014

Koch, L. (2018). Altered splicing in Alzheimer transcriptomes. *Nat Rev Genet, 19*(12), 738-739. doi:10.1038/s41576-018-0064-4

Kosoy, R., Fullard, J. F., Bendl, J., Kleopoulos, S. P., Shao, Z., Argyriou, S., . . . Roussos, P. (2025). Alzheimer's disease transcriptional landscape in ex vivo human microglia. *Nat Neurosci, 28*(9), 1830-1843. doi:10.1038/s41593-025-02020-2

Kracht, M., Muller-Ladner, U., & Schmitz, M. L. (2020). Mutual regulation of metabolic processes and proinflammatory NF-kappaB signaling. *J Allergy Clin Immunol, 146*(4), 694-705. doi:10.1016/j.jaci.2020.07.027

Krausgruber, T., Blazek, K., Smallie, T., Alzabin, S., Lockstone, H., Sahgal, N., . . . Udalova, I. A. (2011). IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. *Nat Immunol, 12*(3), 231-238. doi:10.1038/ni.1990

Langston, P. K., Nambu, A., Jung, J., Shibata, M., Aksoylar, H. I., Lei, J., . . . Horng, T. (2019). Glycerol phosphate shuttle enzyme GPD2 regulates macrophage inflammatory responses. *Nat Immunol, 20*(9), 1186-1195. doi:10.1038/s41590-019-0453-7

Lee, T. W., Kwon, H., Zong, H., Yamada, E., Vatish, M., Pessin, J. E., & Bastie, C. C. (2013). Fyn deficiency promotes a preferential increase in subcutaneous adipose tissue mass and decreased visceral adipose tissue inflammation. *Diabetes, 62*(5), 1537-1546. doi:10.2337/db12-0920

Li, H., Zheng, J., Xu, Q., Yang, Y., Zhou, J., Guo, X., . . . Wu, C. (2023). Hepatocyte Adenosine Kinase Promotes Excessive Fat Deposition and Liver Inflammation. *Gastroenterology, 164*(1), 134-146. doi:10.1053/j.gastro.2022.09.027

Li, P., Zhu, X., Huang, C., Tian, S., Li, Y., Qiao, Y., . . . Tian, D. (2025). Effects of obesity on aging brain and cognitive decline: A cohort study from the UK Biobank. *IBRO Neurosci Rep, 18*, 148-157. doi:10.1016/j.ibneur.2025.01.001

Li, Q. S., Vasanthakumar, A., Davis, J. W., Idler, K. B., Nho, K., Waring, J. F., . . . Alzheimer's Disease Neuroimaging, I. (2021). Association of peripheral blood DNA methylation level with Alzheimer's disease progression. *Clin Epigenetics, 13*(1), 191. doi:10.1186/s13148-021-01179-2

Liao, W. C., Yen, H. R., Chen, C. H., Chu, Y. H., Song, Y. C., Tseng, T. J., & Liu, C. H. (2021). CHPF promotes malignancy of breast cancer cells by modifying syndecan-4 and the tumor microenvironment. *Am J Cancer Res, 11*(3), 812-826. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/33791155

Liberti, M. V., & Locasale, J. W. (2016). The Warburg Effect: How Does it Benefit Cancer Cells? *Trends Biochem Sci, 41*(3), 211-218. doi:10.1016/j.tibs.2015.12.001

Lin, Y., Qiu, T., Wei, G., Que, Y., Wang, W., Kong, Y., . . . Chen, X. (2022). Role of Histone Post-Translational Modifications in Inflammatory Diseases. *Front Immunol, 13*, 852272. doi:10.3389/fimmu.2022.852272

Londhe, P., Yu, P. Y., Ijiri, Y., Ladner, K. J., Fenger, J. M., London, C., . . . Guttridge, D. C. (2018). Classical NF-kappaB Metabolically Reprograms Sarcoma Cells Through Regulation of Hexokinase 2. *Front Oncol, 8*, 104. doi:10.3389/fonc.2018.00104

Lu, A. T., Quach, A., Wilson, J. G., Reiner, A. P., Aviv, A., Raj, K., . . . Horvath, S. (2019). DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging (Albany NY), 11*(2), 303-327. doi:10.18632/aging.101684

Lu, J., Xu, Z., Duan, H., Ji, H., Zhen, Z., Li, B., . . . Zhang, R. (2020). Tumor-associated macrophage interleukin-beta promotes glycerol-3-phosphate dehydrogenase activation, glycolysis and tumorigenesis in glioma cells. *Cancer Sci, 111*(6), 1979-1990. doi:10.1111/cas.14408

Lu, M., Patsouris, D., Li, P., Flores-Riveros, J., Frincke, J. M., Watkins, S., . . . Olefsky, J. M. (2010). A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats. *Am J Physiol Endocrinol Metab, 298*(5), E1036-1048. doi:10.1152/ajpendo.00668.2009

Lundstrom, K., Hromic-Jahjefendic, A., Bilajac, E., Aljabali, A. A. A., Baralic, K., Sabri, N. A., . . . Barh, D. (2023). COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity. *Cell Signal, 101*, 110495. doi:10.1016/j.cellsig.2022.110495

Ma, R., Zhang, X., Li, R., Dong, X., Wang, W., Jiang, Q., . . . Wang, J. (2025). PLSCR1 suppresses SARS-CoV-2 infection by downregulating cell surface ACE2. *J Virol, 99*(3), e0208524. doi:10.1128/jvi.02085-24

Maqbool, A., Lattke, M., Wirth, T., & Baumann, B. (2013). Sustained, neuron-specific IKK/NF-kappaB activation generates a selective neuroinflammatory response promoting local neurodegeneration with aging. *Mol Neurodegener, 8*, 40. doi:10.1186/1750-1326-8-40

Matsubara, T., Nishihara, M., Yasumori, H., Nakai, M., Yanagisawa, K., & Sato, T. (2017). Size and Shape of Amyloid Fibrils Induced by Ganglioside Nanoclusters: Role of Sialyl Oligosaccharide in Fibril Formation. *Langmuir, 33*(48), 13874-13881. doi:10.1021/acs.langmuir.7b02091

McGreevy, K. M., Radak, Z., Torma, F., Jokai, M., Lu, A. T., Belsky, D. W., . . . Horvath, S. (2023). DNAmFitAge: biological age indicator incorporating physical fitness. *Aging (Albany NY), 15*(10), 3904-3938. doi:10.18632/aging.204538

Meen, A. J., Doncheva, A. I., Bottcher, Y., Dankel, S. N., Hoffmann, A., Bluher, M., . . . Kolset, S. O. (2023). Obesity Is Associated with Distorted Proteoglycan Expression in Adipose Tissue. *Int J Mol Sci, 24*(8). doi:10.3390/ijms24086884

Merchant, J. P., Zhu, K., Henrion, M. Y. R., Zaidi, S. S. A., Lau, B., Moein, S., . . . Chang, R. (2023). Predictive network analysis identifies JMJD6 and other potential key drivers in Alzheimer's disease. *Commun Biol, 6*(1), 503. doi:10.1038/s42003-023-04791-5

Merida, I., Arranz-Nicolas, J., Rodriguez-Rodriguez, C., & Avila-Flores, A. (2019). Diacylglycerol kinase control of protein kinase C. *Biochem J, 476*(8), 1205-1219. doi:10.1042/BCJ20180620

Meur, S., & Karati, D. (2025). Fyn Kinase in Alzheimer's Disease: Unraveling Molecular Mechanisms and Therapeutic Implications. *Mol Neurobiol, 62*(1), 643-660. doi:10.1007/s12035-024-04286-2

Morel, M., & Long, W. (2024). FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. *Mol Oncol, 18*(3), 762-777. doi:10.1002/1878-0261.13554

Ndhlovu, L. C., Bendall, M. L., Dwaraka, V., Pang, A. P. S., Dopkins, N., Carreras, N., . . . Corley, M. J. (2024). Retro-age: A unique epigenetic biomarker of aging captured by DNA methylation states of retroelements. *Aging Cell, 23*(10), e14288. doi:10.1111/acel.14288

Neutzner, M., Kohler, C., Frank, S., Killer, H. E., & Neutzner, A. (2023). Impact of aging on meningeal gene expression. *Fluids Barriers CNS, 20*(1), 12. doi:10.1186/s12987-023-00412-9

Nunez-Alvarez, Y., & Suelves, M. (2022). HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes. *FEBS J, 289*(10), 2771-2792. doi:10.1111/febs.15895

Oh, S., Jo, S., Bajzikova, M., Kim, H. S., Dao, T. T. P., Rohlena, J., . . . Park, S. (2023). Non-bioenergetic roles of mitochondrial GPD2 promote tumor progression. *Theranostics, 13*(2), 438-457. doi:10.7150/thno.75973

Oh, S., Mai, X. L., Kim, J., de Guzman, A. C. V., Lee, J. Y., & Park, S. (2024). Glycerol 3-phosphate dehydrogenases (1 and 2) in cancer and other diseases. *Exp Mol Med, 56*(5), 1066-1079. doi:10.1038/s12276-024-01222-1

Oikawa, N., Matsubara, T., Fukuda, R., Yasumori, H., Hatsuta, H., Murayama, S., . . . Yanagisawa, K. (2015). Imbalance in fatty-acid-chain length of gangliosides triggers

Alzheimer amyloid deposition in the precuneus. *PLoS One, 10*(3), e0121356. doi:10.1371/journal.pone.0121356

Pai, P., & Sukumar, S. (2020). HOX genes and the NF-kappaB pathway: A convergence of developmental biology, inflammation and cancer biology. *Biochim Biophys Acta Rev Cancer, 1874*(2), 188450. doi:10.1016/j.bbcan.2020.188450

Panicker, N., Sarkar, S., Harischandra, D. S., Neal, M., Kam, T. I., Jin, H., . . . Kanthasamy, A. (2019). Fyn kinase regulates misfolded alpha-synuclein uptake and NLRP3 inflammasome activation in microglia. *J Exp Med, 216*(6), 1411-1430. doi:10.1084/jem.20182191

Pantaleo, E., Monaco, A., Amoroso, N., Lombardi, A., Bellantuono, L., Urso, D., . . . Bellotti, R. (2022). A Machine Learning Approach to Parkinson's Disease Blood Transcriptomics. *Genes (Basel), 13*(5). doi:10.3390/genes13050727

Parker, D., Davidson, K., Osmulski, P. A., Gaczynska, M., & Pickering, A. M. (2025). Proteasome Augmentation Mitigates Age-Related Cognitive Decline in Mice. *Aging Cell, 24*(3), e14492. doi:10.1111/acel.14492

Patysheva, M. R., Prostakishina, E. A., Budnitskaya, A. A., Bragina, O. D., & Kzhyshkowska, J. G. (2023). Dual-Specificity Phosphatases in Regulation of Tumor-Associated Macrophage Activity. *Int J Mol Sci, 24*(24). doi:10.3390/ijms242417542

Pramfalk, C., Eriksson, M., & Parini, P. (2015). Role of TG-interacting factor (Tgif) in lipid metabolism. *Biochim Biophys Acta, 1851*(1), 9-12. doi:10.1016/j.bbalip.2014.07.019

Qi, J., Wu, G., He, M., Xu, Y., Yang, Z., Ding, L., . . . Zhang, Z. (2024). CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers. *Aging (Albany NY), 16*(2), 1879-1896. doi:10.18632/aging.205465

Qi, Q., Menzaghi, C., Smith, S., Liang, L., de Rekeneire, N., Garcia, M. E., . . . Qi, L. (2012). Genome-wide association analysis identifies TYW3/CRYZ and NDST4 loci associated with circulating resistin levels. *Hum Mol Genet, 21*(21), 4774-4780. doi:10.1093/hmg/dds300

Qu, H., Gong, X., Liu, X., Zhang, R., Wang, Y., Huang, B., . . . Zheng, Y. (2021). Deficiency of Mitochondrial Glycerol 3-Phosphate Dehydrogenase Exacerbates Podocyte Injury and the Progression of Diabetic Kidney Disease. *Diabetes, 70*(6), 1372-1387. doi:10.2337/db20-1157

Qu, L., Tang, Y., Wu, J., Yun, X., Lo, H. H., Song, L., . . . Law, B. Y. K. (2024). FBXL16: a new regulator of neuroinflammation and cognition in Alzheimer's disease through the ubiquitination-dependent degradation of amyloid precursor protein. *Biomark Res, 12*(1), 144. doi:10.1186/s40364-024-00691-w

Rahman, R. I., T.; Shahjaman; Holsinger, D. Moni, M.A. (2018). Common molecular biomarker signatures in blood and brain of Alzheimer's disease. *bioRxiv*, 1-19. doi:https://doi.org/10.1101/482828

Rattanapan, Y., Duangchan, T., Sai-Ong, T., & Chareonsirisuthigul, T. (2025). miR-4428 and miR-185-5p as Key Modulators of Insulin Sensitivity and Glucose Homeostasis: Insights into Pathways and Therapeutic Potential in Type 2 Diabetes Mellitus. *Biology (Basel), 14*(4). doi:10.3390/biology14040424

Reading, C. (2024). Bezisterim Effects on Biological Age, Alzheimer's Epigenetics, and Neurologic Assessments. Presentation at ARDD; Copenhagen, Denmark; 2024.

Reading, C. L., Flores-Riveros, J., Stickney, D. R., & Frincke, J. M. (2013). An anti-inflammatory sterol decreases obesity-related inflammation-induced insulin resistance and metabolic dysregulation. *Mediators Inflamm, 2013*, 814989. doi:10.1155/2013/814989

Reading, C. L., Frincke, J. M., & White, S. K. (2012). Molecular targets for 17alpha-ethynyl-5-androstene-3beta,7beta,17beta-triol, an anti-inflammatory agent derived from the human metabolome. *PLoS One, 7*(2), e32147. doi:10.1371/journal.pone.0032147

Reading, C. L., Stickney, D. R., Flores-Riveros, J., Destiche, D. A., Ahlem, C. N., Cefalu, W. T., & Frincke, J. M. (2013). A synthetic anti-inflammatory sterol improves insulin sensitivity in insulin-resistant obese impaired glucose tolerance subjects. *Obesity (Silver Spring), 21*(9), E343-349. doi:10.1002/oby.20207

Reading, C. L., Yan, J., Testa, M. A., Simonson, D. C., Javaid, H., Schmunk, L., . . . Palumbo, J. (2025). An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease. *Front Neurosci, 19*, 1516746. doi:10.3389/fnins.2025.1516746

Reading, C. Y., J.; Schmunk, L.; Martin-Herranz, D.; Ahlem, C.; Markham, P.; O'Quinn, S.; Palumbo, J. (2025). Bezisterim Epigenetic Effects on Aging and Neurodegeneration. Presented at: 7th World Aging and Rejuvenation Conference; July 9-10, 2025; Vienna, Austria.

Ren, J., Chen, X., & Chen, Z. J. (2014). IKKbeta is an IRF5 kinase that instigates inflammation. *Proc Natl Acad Sci U S A, 111*(49), 17438-17443. doi:10.1073/pnas.1418516111

Rorbach-Dolata, A., & Piwowar, A. (2019). Neurometabolic Evidence Supporting the Hypothesis of Increased Incidence of Type 3 Diabetes Mellitus in the 21st Century. *Biomed Res Int, 2019*, 1435276. doi:10.1155/2019/1435276

Saddala, M. S., Yang, X., Tang, S., & Huang, H. (2021). Transcriptome-wide analysis reveals core sets of transcriptional regulators of sensome and inflammation genes in retinal microglia. *Genomics, 113*(5), 3058-3071. doi:10.1016/j.ygeno.2021.07.001

Sanchez-Mut, J. V., Aso, E., Heyn, H., Matsuda, T., Bock, C., Ferrer, I., & Esteller, M. (2014). Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer's disease. *Hippocampus, 24*(4), 363-368. doi:10.1002/hipo.22245

Sanchez-Mut, J. V., & Graff, J. (2015). Epigenetic Alterations in Alzheimer's Disease. *Front Behav Neurosci, 9*, 347. doi:10.3389/fnbeh.2015.00347

Sato, A., Nagai, M., Tagami, A., Natori, Y., & Okada, M. (1991). Effect of pyridoxine-deficiency on degradation of cytosolic aspartate aminotransferase in rat liver lysosomes. *J Nutr Sci Vitaminol (Tokyo), 37*(4), 419-424. doi:10.3177/jnsv.37.419

Sehgal, R., Markov, Y., Qin, C., Meer, M., Hadley, C., Shadyab, A. H., . . . Levine, M. (2025). Systems Age: a single blood methylation test to quantify aging heterogeneity across 11 physiological systems. *Nat Aging, 5*(9), 1880-1896. doi:10.1038/s43587-025-00958-3

Sha, Y. L., Liu, Y., Yang, J. X., Wang, Y. Y., Gong, B. C., Jin, Y., . . . Zhao, Q. (2022). B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met/AKT/mTOR/IRF-1 axis in neuroblastoma. *J Exp Clin Cancer Res, 41*(1), 314. doi:10.1186/s13046-022-02523-x

Shaughness, M., Acs, D., Brabazon, F., Hockenbury, N., & Byrnes, K. R. (2020). Role of Insulin in Neurotrauma and Neurodegeneration: A Review. *Front Neurosci, 14*, 547175. doi:10.3389/fnins.2020.547175

Srinivasan, K., Friedman, B. A., Etxeberria, A., Huntley, M. A., van der Brug, M. P., Foreman, O., . . . Hansen, D. V. (2020). Alzheimer's Patient Microglia Exhibit Enhanced Aging and Unique Transcriptional Activation. *Cell Rep, 31*(13), 107843. doi:10.1016/j.celrep.2020.107843

Sugimoto-Ishige, A., Jodo, A., & Tanaka, T. (2025). Fbxo16 mediates degradation of NF-kappaB p65 subunit and inhibits inflammatory response in dendritic cells. *Front Immunol, 16*, 1524110. doi:10.3389/fimmu.2025.1524110

Sun, L., Marin de Evsikova, C., Bian, K., Achille, A., Telles, E., Pei, H., & Seto, E. (2018). Programming and Regulation of Metabolic Homeostasis by HDAC11. *EBioMedicine, 33*, 157-168. doi:10.1016/j.ebiom.2018.06.025

Sun, S., Han, Y., Zhang, C., Liu, H., Wang, B., Cao, S., . . . Chen, Y. (2022). Adenosine Kinase Inhibition Prevents Severe Acute Pancreatitis via Suppressing Inflammation and Acinar Cell Necroptosis. *Front Cell Dev Biol, 10*, 827714. doi:10.3389/fcell.2022.827714

Tan, S., Wang, Z., Li, N., Guo, X., Zhang, Y., Ma, H., . . . Ma, C. (2023). Transcription factor Zhx2 is a checkpoint that programs macrophage polarization and antitumor response. *Cell Death Differ, 30*(9), 2104-2119. doi:10.1038/s41418-023-01202-4

Teschendorff, A. E. (2020). A comparison of epigenetic mitotic-like clocks for cancer risk prediction. *Genome Med, 12*(1), 56. doi:10.1186/s13073-020-00752-3

TGIF1. (2025). TGFB induced factor homeobox 1. Retrieved from https://www.ncbi.nlm.nih.gov/gene/7050

Tikhanovich, I., Kuravi, S., Artigues, A., Villar, M. T., Dorko, K., Nawabi, A., . . . Weinman, S. A. (2015). Dynamic Arginine Methylation of Tumor Necrosis Factor (TNF) Receptor-associated Factor 6 Regulates Toll-like Receptor Signaling. *J Biol Chem, 290*(36), 22236-22249. doi:10.1074/jbc.M115.653543

Tomusiak, A., Floro, A., Tiwari, R., Riley, R., Matsui, H., Andrews, N., . . . Verdin, E. (2024). Development of an epigenetic clock resistant to changes in immune cell composition. *Commun Biol, 7*(1), 934. doi:10.1038/s42003-024-06609-4

Tong, H., Dwaraka, V. B., Chen, Q., Luo, Q., Lasky-Su, J. A., Smith, R., & Teschendorff, A. E. (2024). Quantifying the stochastic component of epigenetic aging. *Nat Aging, 4*(6), 886-901. doi:10.1038/s43587-024-00600-8

Tsai, M. H., & Lee, C. K. (2018). STAT3 Cooperates With Phospholipid Scramblase 2 to Suppress Type I Interferon Response. *Front Immunol, 9*, 1886. doi:10.3389/fimmu.2018.01886

Unoki, M., Masuda, A., Dohmae, N., Arita, K., Yoshimatsu, M., Iwai, Y., . . . Nakamura, Y. (2013). Lysyl 5-hydroxylation, a novel histone modification, by Jumonji domain containing 6 (JMJD6). *J Biol Chem, 288*(9), 6053-6062. doi:10.1074/jbc.M112.433284

van Dongen, J., Nivard, M. G., Baselmans, B. M., Zilhao, N. R., Ligthart, L., Consortium, B., . . . Boomsma, D. I. (2015). Epigenome-Wide Association Study of Aggressive Behavior. *Twin Res Hum Genet, 18*(6), 686-698. doi:10.1017/thg.2015.74

Vervoorts, J., Neumann, D., & Luscher, B. (2020). The CCNY (cyclin Y)-CDK16 kinase complex: a new regulator of autophagy downstream of AMPK. *Autophagy, 16*(9), 1724-1726. doi:10.1080/15548627.2020.1795423

Wang, C., Zhang, P., Li, Y., Wang, X., Guo, L., Li, J., & Jiao, H. (2023). Downregulation of TRIM27 alleviates hypoxic-ischemic encephalopathy through inhibiting inflammation and microglia cell activation by regulating STAT3/HMGB1 axis. *J Chem Neuroanat, 129*, 102251. doi:10.1016/j.jchemneu.2023.102251

Wang, N., Liang, H., & Zen, K. (2014). Molecular mechanisms that influence the macrophage m1-m2 polarization balance. *Front Immunol, 5*, 614. doi:10.3389/fimmu.2014.00614

Wang, T., Villegas, S., Huang, Y., White, S. K., Ahlem, C., Lu, M., . . . Flores-Riveros, J. (2010). Amelioration of glucose intolerance by the synthetic androstene HE3286: link to inflammatory pathways. *J Pharmacol Exp Ther, 333*(1), 70-80. doi:10.1124/jpet.109.161182

Wang, X., Shi, N., Hui, M., Jin, H., Gao, S., Zhou, Q., . . . Shen, H. (2021). The Impact of beta-1,4-Galactosyltransferase V on Microglial Function. *Front Cell Neurosci, 15*, 723308. doi:10.3389/fncel.2021.723308

Wang, Z., Kong, L., Tan, S., Zhang, Y., Song, X., Wang, T., . . . Ma, C. (2020). Zhx2 Accelerates Sepsis by Promoting Macrophage Glycolysis via Pfkfb3. *J Immunol, 204*(8), 2232-2241. doi:10.4049/jimmunol.1901246

Ward, A. J., Rimer, M., Killian, J. M., Dowling, J. J., & Cooper, T. A. (2010). CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. *Hum Mol Genet, 19*(18), 3614-3622. doi:10.1093/hmg/ddq277

Wei, L., Tian, Y., Chen, Y., Wei, Q., Chen, F., Cao, B., . . . Wang, K. (2019). Identification of TYW3/CRYZ and FGD4 as susceptibility genes for amyotrophic lateral sclerosis. *Neurol Genet, 5*(6), e375. doi:10.1212/NXG.0000000000000375

Wei, Y., & Li, X. (2022). Different phenotypes of microglia in animal models of Alzheimer disease. *Immun Ageing, 19*(1), 44. doi:10.1186/s12979-022-00300-0

Wu, S., Mao, C., Kondiparthi, L., Poyurovsky, M. V., Olszewski, K., & Gan, B. (2022). A ferroptosis defense mechanism mediated by glycerol-3-phosphate dehydrogenase 2 in mitochondria. *Proc Natl Acad Sci U S A, 119*(26), e2121987119. doi:10.1073/pnas.2121987119

Wunderlich, F. T., Luedde, T., Singer, S., Schmidt-Supprian, M., Baumgartl, J., Schirmacher, P., . . . Bruning, J. C. (2008). Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. *Proc Natl Acad Sci U S A, 105*(4), 1297-1302. doi:10.1073/pnas.0707849104

Xu, Y., Wang, Y., Yan, S., Yang, Q., Zhou, Y., Zeng, X., . . . Huo, Y. (2017). Regulation of endothelial intracellular adenosine via adenosine kinase epigenetically modulates vascular inflammation. *Nat Commun, 8*(1), 943. doi:10.1038/s41467-017-00986-7

Yanagisawa, K. (2015). GM1 ganglioside and Alzheimer's disease. *Glycoconj J, 32*(3-4), 87-91. doi:10.1007/s10719-015-9579-5

Yee, B. K., Singer, P., Chen, J. F., Feldon, J., & Boison, D. (2007). Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. *Eur J Neurosci, 26*(11), 3237-3252. doi:10.1111/j.1460-9568.2007.05897.x

Ying, K., Liu, H., Tarkhov, A. E., Sadler, M. C., Lu, A. T., Moqri, M., . . . Gladyshev, V. N. (2024). Causality-enriched epigenetic age uncouples damage and adaptation. *Nat Aging, 4*(2), 231-246. doi:10.1038/s43587-023-00557-0

You, J. E., Kim, E. J., Kim, H. W., Kim, J. S., Kim, K., & Kim, P. H. (2024). Exploring the Role of Guanylate-Binding Protein-2 in Activated Microglia-Mediated Neuroinflammation and Neuronal Damage. *Biomedicines, 12*(5). doi:10.3390/biomedicines12051130

Yu, X., Rehman, A. U., Dang, L., Zhang, X., Liu, J., Xiong, X., . . . Jian, Z. (2025). Interferon regulatory factor 5: a potential target for therapeutic intervention in inflammatory diseases. *Front Immunol, 16*, 1535823. doi:10.3389/fimmu.2025.1535823

Zarrella, J. A., & Tsurumi, A. (2024). Genome-wide transcriptome profiling and development of age prediction models in the human brain. *Aging (Albany NY), 16*(5), 4075-4094. doi:10.18632/aging.205609

Zhang, L., Silva, T. C., Young, J. I., Gomez, L., Schmidt, M. A., Hamilton-Nelson, K. L., . . . Wang, L. (2020). Epigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer's disease. *Nat Commun, 11*(1), 6114. doi:10.1038/s41467-020-19791-w

Zhang, Q., Xia, Y., Wang, Y., Shentu, Y., Zeng, K., Mahaman, Y. A. R., . . . Wang, X. (2018). CK2 Phosphorylating I(2)(PP2A)/SET Mediates Tau Pathology and Cognitive Impairment. *Front Mol Neurosci, 11*, 146. doi:10.3389/fnmol.2018.00146

Zhao, S., Chen, F., Hu, L., Li, X., Gao, Z., Chen, M., . . . Song, Z. (2025). Long non-coding rnas as key modulators of the immune microenvironment in hepatocellular carcinoma: implications for Immunotherapy. *Front Immunol, 16*, 1523190. doi:10.3389/fimmu.2025.1523190

Zhong, Q., Jiang, K., Zhang, F., Tian, Y., Gu, J., Li, T., . . . Sun, F. (2023). Exploring the correlation of glycolysis-related chondroitin polymerizing factor (CHPF) with clinical characteristics, immune infiltration, and cuproptosis in bladder cancer. *Am J Cancer Res, 13*(6), 2213-2233. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/37424829

Zhou, J., Simon, J. M., Liao, C., Zhang, C., Hu, L., Zurlo, G., . . . Zhang, Q. (2022). An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. *Mol Cell, 82*(16), 3030-3044 e3038. doi:10.1016/j.molcel.2022.06.003

Zhou, Y., & Wu, Q. (2023). Spotlight on HOX cluster☐embedded antisense lncRNAs in cardiovascular diseases (Review). *Int J Mol Med, 52*(6). doi:10.3892/ijmm.2023.5317

Zhou, Z., Zhong, L., Chu, X., Wan, P., Dan, W., Shao, X., . . . Liu, B. (2023). HDAC11 mediates the ubiquitin-dependent degradation of p53 and inhibits the anti-leukemia effect of PD0166285. *Med Oncol, 40*(11), 325. doi:10.1007/s12032-023-02196-2

Tables

Table 1. Genes with potentially beneficial changes with DPM genes identified in Figure 2.

Increased DPM Genes	Promoter CpGs	DPM	*P* FDR < 0.05	Activity
HOXA4	15	+13%	1.6e-6	TF, epigenetic neuropathology, cognitive decline, inflammation, and atherosclerosis (Q. S. Li et al., 2021; Pai & Sukumar, 2020; Y. Zhou & Wu, 2023)
TYW3	15	+31%	2.6e-6	IR; aberrant ubiquitination in ALS, AD (Akrioti et al., 2022; Q. Qi et al., 2012; L. Wei et al., 2019)
B3GALT4	50	+6%	2.7e-5	Hypomethylated in AD brain, microglial neuroinflammation, pro-inflammatory kinase cascades, lipid dysregulation, neurodegeneration, and cognition (*B3GALT4*, 2025; Hayashi et al., 2004; Matsubara et al., 2017; Oikawa et al., 2015; Sha et al., 2022; X. Wang et al., 2021; Yanagisawa, 2015)
CRYZ	13	+31%	1.8e-4	IR, aberrant ubiquitination in ALS, and AD (Akrioti et al., 2022; Y. Wei & Li, 2022)
CHPF	16	+11%	0.0007	Prion disease, inflammation, cognition, glycolysis, and obesity (Avram, Shaposhnikov, Buiu, & Mernea, 2014; Huynh et al., 2019; Liao et al., 2021; Meen et al., 2023; Zhong et al., 2023)
IKBKG	20	+6%	0.0011	Microglial neuroinflammation, kinase cascades, cognitive decline, neuron loss, glycolysis, M1 polarization, T2D, and obesity (Alanazi et al., 2025; Kracht, Muller-Ladner, & Schmitz, 2020; Londhe et al., 2018; Maqbool, Lattke, Wirth, & Baumann, 2013; N. Wang, Liang, & Zen, 2014; Wunderlich et al., 2008)
TGIF1	23	+7%	0.0014	TF, inflammation, endothelial cytokines, dysregulated phosphoprotein, lipid, cholesterol, and chromatin remodeling (Chang et al., 2024; Friend, 2023; He et al., 2021; Hneino et al., 2012; Pramfalk, Eriksson, & Parini, 2015; *TGIF1*, 2025)
TRIM27	31	+11%	0.0014	Brain aging, obesity, cognitive decline, microglial neuroinflammation, significantly increased concentration in AD plasma (Ali et al., 2025; Kang, 2022; P. Li et al., 2025; C. Wang et al., 2023)
HDAC11	20	+9%	0.0015	Microglial neuroinflammation, Aβ, cognitive decline, lipid dysregulation, T2D, obesity, MAPK cascades, dysregulated phosphoprotein, cholesterol, obesity, and glycolysis (Bahl & Seto, 2021; Bai et al., 2025; Bi et al., 2021; Cao et al., 2019; H. Chen, Xie, Chen, & Zhuang, 2022; Nunez-Alvarez & Suelves, 2022; L. Sun et al., 2018; S. Sun et al., 2022; Z. Zhou et al., 2023)
ZHX2	7	+8%	0.001	TF, atherosclerosis, apoptosis, lipid, macrophage inflammation, M1 polarization, increased in AD plasma (Ali et al., 2025; Erbilgin et al., 2018; Tan et al., 2023; Z. Wang et al., 2020)
CUTA	49	+5%	0.0016	Cognitive decline, Aβ processing, increased in AD plasma (Ali et al., 2025; Hou et al., 2015)
DGKZ	15	+6%	0.0017	Cognitive decline, kinase cascades, T2D, obesity, lipid, and cholesterol dysregulation (Begin, 2016; Benziane et al., 2017; Merida, Arranz-Nicolas, Rodriguez-Rodriguez,

				& Avila-Flores, 2019)

Increased DPM Genes	Promoter CpGs	DPM	*P* FDR < 0.05	Activity
FYN	15	+11%	0.0021	Kinase cascades, neurotoxicity and synaptic impairments caused by Aβ, tau tyrosine phosphorylation, cognitive decline, microglial neuroinflammation, inflammasome, IR, and T2D (Bastie et al., 2007; Guglietti, Sivasankar, Mustafa, Corrigan, & Collins-Praino, 2021; Lee et al., 2013; Meur & Karati, 2025; Panicker et al., 2019)
GPD2	14	+6%	0.0021	Microglial neuroinflammation, M1 polarization, T2D, glycolysis, and lipid ferroptosis (*GDP2*, 2024; Langston et al., 2019; J. Lu et al., 2020; Oh et al., 2023; Oh et al., 2024; H. Qu et al., 2021; Wu et al., 2022; You et al., 2024)
JMJD6	18	+6%	0.0024	Cognitive decline, driver of AD network, Abeta, pTau, inflammation, *TRAF6*, NFκB, obesity, lipid metabolism; increased in AD plasma; nominated aging and AD target, forms 5-OH-lysine on histones and inhibits methylation (J. Agora, n.d.; Ali et al., 2025; Hu et al., 2015; Merchant et al., 2023; Tikhanovich et al., 2015; Unoki et al., 2013; J. Zhou et al., 2022)
CELF1	28	+6%	0.0028	Inflammation, muscle wasting, nominated aging, and AD target (C. Agora, n.d.; Ward, Rimer, Killian, Dowling, & Cooper, 2010)
IRF5	14	+8%	0.0028	TF, chromatin remodeling, microglial neuroinflammation, Aβ pathology, M1 polarization, glycolysis, obesity, T2D, kinase cascades, and dysregulated phosphoprotein (Dalmas et al., 2015; Fang et al., 2023; Krausgruber et al., 2011; Ren, Chen, & Chen, 2014; Yu et al., 2025)
ADK	25	+5%	0.0031	Kinase cascades, inflammation, lipid dysregulation, cognitive decline (Ahmad et al., 2014; H. Li et al., 2023; S. Sun et al., 2022; Xu et al., 2017; Yee, Singer, Chen, Feldon, & Boison, 2007)
CSNK2B	31	7%	0.0033	Kinase cascades, pTau, cognitive decline, astroglial neuroinflammation, increased in AD and FTD plasma (Ali et al., 2025; Rorbach-Dolata & Piwowar, 2019; Q. Zhang et al., 2018)
Decreased DPM Genes	**Promoter CpGs**	**DPM**	***P* FDR < 0.05**	**Activity**
CDK16	18	-13%	0.002	Autophagy, decreased inflammatory gene expression and immune infiltration, suppressed M1 polarization, reduced Tau aggregation, enhanced neuronal function and survival (Garwain, Yerramilli, Romero, & Scarlata, 2020; J. Qi et al., 2024; Vervoorts, Neumann, & Luscher, 2020; C. Wang et al., 2023)
DUSP22	8	-7%	0.004	Anti-inflammatory phosphatase, hypermethylated in AD, expression decreases inflammatory kinase cascades and dysregulated phosphoproteins, decreases pTau, DNAm correlates with Braak stages, cognitive decline, PTSD and schizophrenia, expression is negatively correlated with glucose, obesity, cholesterol, and M1 polarization (An et al., 2021; Boks et al., 2018; Ge et al., 2022; Howie, Rijal, & Ressler, 2019; Patysheva, Prostakishina, Budnitskaya,

				Bragina, & Kzhyshkowska, 2023; Sanchez-Mut et al., 2014; Sanchez-Mut & Graff, 2015)
UBE2C	16	-11%	0.007	Reduces inflammation primarily by blocking the activation of NF-κB, can mitigate age-related cognitive decline, decreases inflammatory NFκB-related kinase cascades, decreased in AD plasma (Ali et al., 2025; Chitra, Nalini, & Rajasekhar, 2012; Elliott, Zollner, & Boehncke, 2003; Parker, Davidson, Osmulski, Gaczynska, & Pickering, 2025)
Decreased DPM Genes	**Promoter CpGs**	**DPM**	**P FDR < 0.05**	**Activity**
PLSCR2	7	-6%	0.010	Suppresses inflammation and M1 polarization, suppresses COVID by downregulating ACE2 (Ali et al., 2025; Lundstrom et al., 2023; Ma et al., 2025; Tsai & Lee, 2018)
NME3	8	-18%	0.016	Required for cell survival, reduces ROS and inflammation, and is required ciliary function (C. W. Chen, Tsao, Zhang, & Chang, 2020; Hoff et al., 2018)
SP140	6	-7%	0.024	Epigenetic reader that represses lineage-inappropriate genes such as HOX to maintain macrophage identity, differentially expressed in microglial neuroinflammation, decreases inflammatory gene expression, decreased transcripts in AD microglia with dementia and Braak stage (Citron et al., 2015; Fraschilla & Jeffrey, 2020; Karaky et al., 2018; Kosoy et al., 2025; Saddala, Yang, Tang, & Huang, 2021)
SLC9B2	22	-7%	0.025	Increases aging insulin signaling; absence of this protein leads to enhanced aging and obesity-induced glucose intolerance; maintains intracellular pH to inhibit shifting macrophages toward a pro-inflammatory (M1) phenotype; polarization and glycolysis; decreased transcripts in AD plasma with Braak stage and with dementia (Anderegg, Gyimesi, Ho, Hediger, & Fuster, 2022; Deisl et al., 2016; Kosoy et al., 2025)
LINC01806	3	-17%	0.026	Downregulated in AD with cognitive impairments, blood biomarker for cognitive impairment, decreases miR-44428 to improve insulin sensitivity and glucose homeostasis (Pantaleo et al., 2022; Rahman, 2018; Rattanapan, Duangchan, Sai-Ong, & Chareonsirisuthigul, 2025)
PARD6G-AS1	5	-10%	0.027	Cognition; correlation between methylation and aggressive behavior (van Dongen et al., 2015)
SSBP4	4	-9%	0.038	Improved cognition; transcription decreased with brain aging and cognitive decline (Zarrella & Tsurumi, 2024)
MAMSTR	7	-9%	0.038	Highly significant hypermethylated region in AD associated with Braak stages, microglial neuroinflammation, and cognitive decline; anti-inflammatory transcriptional coactivator of MEF2C that restrains microglial inflammatory response and is lost in brain aging in an IFN-I-dependent manner (Deczkowska et al., 2017; L. Zhang et al., 2020)
MIR4458HG	5	-6%	0.038	Decreases M1 polarization; increased expression promotes M2 (Zhao et al., 2025)
ISOC2	6	-9%	0.041	Maintains mitochondrial integrity, decreases inflammation related to senescence, and inhibits INK4a (ISOC2, 2025; Sato, Nagai, Tagami, Natori, & Okada, 1991)

Decreased DPM Genes	Promoter CpGs	DPM	P FDR < 0.05	Activity
SLC28A2-AS1	6	-11%	0.043	Improves cognition–*SLC28A2* is upregulated in aging brain, and may contribute to AD neurodegeneration (Aykac & Sehirli, 2020; Neutzner, Kohler, Frank, Killer, & Neutzner, 2023)
FXBL16	3	-19%	0.047	Accelerates degradation of APP, decreases microglial and astrocyte neuroinflammation and cognitive impairments, increased IRS1 stabilization and insulin signaling, decreases M1 polarization and kinase cascades and glycolysis, nominated aging and AD target (F. Agora, n.d.; Kim et al., 2021; Morel & Long, 2024; L. Qu et al., 2024; Sugimoto-Ishige, Jodo, & Tanaka, 2025)

Note: Potentially beneficial activities for genes with significantly increased or decreased DPM were identified and referenced. The table also includes the number of promoter CpGs identified, the DPM percentage, and the FDR < 0.05-*P* value for each gene.

Table 2. Shared PBDPM genes.

	Genes	Inflammation	%	Shared
Clock				
PCHorvath2	9	9	100	56
PCHannum	1	1	100	5
PCGrimAge	3	2	67	13
DamAge	5	5	100	39
IntrinClock	7	6	86	42
StocZhang	5	5	100	34
StocHorvath1	9	7	78	45
StocPhenoAge	12	10	83	64
RetroClock1&2	6	6	100	34
Clock-unique gene total	45	39	87	249
Traits				
Inflammation	355	355	100	1459
Cognition	189	153	81	887
T2D	156	125	80	837
Obesity	148	120	81	802
M1 polarization	146	136	93	759
Kinase cascades	143	127	89	722
Lipids	120	99	83	672
Glycolysis	90	69	77	498
Phosphoproteins	76	58	76	378
Nominated targets	37	31	84	202
Chromatin remodeling	75	68	91	398
Transcription Factors	78	67	86	409
Trait-unique gene total	448	355	79	1614
Clock- and trait-unique gene total	448	355	79	1671
Transcription				
Clock gene TF	7	6	86	44*
Unique PBDPM TFs associated with PBDPM gene transcription	40	33	89	190
Unique PBDPM genes transcribed by PBDPM TFs	438**	350	80	1651
Control				
SOMAscan&OLINK	113	0	0	0

Note: For the potentially beneficial DPM genes identified, this table presents the number of genes; the number and percentage associated with inflammation; the total number of shared genes for each clock or trait, including transcription factors; and information related to PBDPM transcription by PBDPM transcription factors.

*Forty-three of the 45 age deceleration clock genes can be transcribed by three TFs: *RUNX2*, *STAT3,* and *TCF12*.

**Four hundred thirty-eight of 448 PBDPM genes can be transcribed by the 78 PBDPM TFs; the other 10 genes do not have significantly identified TFs.

Figures

Figure 1. Decelerated aging in first- and second-generation aging clocks after 30 weeks of treatment with bezisterim. (A-K) Mean ± SE EAA of DNA samples from patients with AD following 7 months of treatment with bezisterim (green, n = 17) or placebo (orange, n = 16), as predicted by the following established aging clocks: PCHorvath2 **(A)**, PCHannum **(B)**, PCGrimAge **(C)**, DamAge **(D)**, IntrinClock **(E)**, StochasticZhang **(F)**, StochasticHorvath **(G)**, StochasticPhenoAge **(H)**, RetroClock **(I)**, RetroClockv2 **(J)**, and SystemsAge **(K)**. Positive differences between model-predicted biological age and chronological age indicate accelerated aging, whereas negative differences indicate decelerated aging. The rate of age acceleration

across all evaluated clocks was statistically significantly reduced in samples from bezisterim-treated AD patients (n = 17 samples/clock) vs samples from placebo-treated AD patients (n = 16 samples/clock). Between-group differences in EAAs were estimated by calculating the residual of the clock to age, and adjusting for sex, first 3 potential components, and genotype. Statistical tests used were paired Wilcoxon rank sum tests between the pre- and post-test.

Figure 2. Differences in DPM genes following 7 months of treatment with bezisterim or placebo. (A-B) Treatment-dependent differences in promoter methylation are shown for all 2154 DPM genes with statistically significant FDR adjusted P values, at an adjusted level of $P < 0.001$ (**A**) or 441 potentially beneficial DPM genes within an adjusted level of $P > 0.001$ and $P < 0.05$ (**B**). Average between-group differences in promoter methylation were computed for each of 448 genes. Positive and negative values indicate relative between-group decreases and increases in gene expression, respectively.

Figure 3. PBDPM Clock Genes. 45 Shared Clock PBDPM genes shared between 9 EAA clocks, 12 reported aging and AD traits, and AD, PD, and FTD, reported AD microglial dementia and Braak pathology scores, and details for PBDPM transcription factors that are known to transcribe the PBDPM genes.

Columns (left to right): UCSC_RefGene_Name | PCHorvath2 EAA | PCHannum EAA | PCGrimAge EAA | DamAge EAA | IntrinClock EAA | Stoch Zhang EAA | Stoch Horvath EAA | Stoch PhenoAge EAA | RetroClock V1/2 EAA | Inflammation | Cognition | Type 2 Diabetes | Obesity | M1 polarization | Kinase Cascade | Lipids | Glycolysis | Phosphoprotein | Nominated | Chromatin Reg. | Transcription | Shared | AD Proteomics | PD Proteomics | FTD Proteomics | Dementia Transcripts | Braak Transcripts | TF transcribing | PBDPM genes | Transcribed by PBDPM TF | No significant TF association

UCSC_RefGene_Name	Shared
AAK1	5
ABCA2	5
ABHD14A	4
ABHD14B	1
ABR	7
ACACA	6
ACAP1	5
ACAT2	6
ACBD4	2
ACOT8	4
ACOT9	5
ACP5	4
ACP6	7
ACVR1B	5
ADIPOR1	1
ADIPOR2	2
ADK	4
AGAP3	4
AGGF1	3
AHCY	2
AHCYL1	4
ALDH4A1	3
ALG3	1
AMPD2	2
AMPD3	5
ANKRA2	3
ANP32E	2
ANXA11	1
ANXA6	6
APPL2	2
ARF6	3
ARHGAP25	3
ARRB2	7
ARRDC3	6
ASF1B	2
ATAD3A	4
ATE1-AS1	1
ATG16L2	1
ATIC	1
ATR	2
AUP1	1
AZI2	2
B3GALT4	3
BAZ2A	2
BCAT1	5
BCL3	7
BHLHE40	7
BMP8B	1
BRCC3	1
BRD2	8
BTK	6
C1RL	3
C2	4
C6orf120	2
CACNA1C	4
CACNB3	3
CAMK2D	8
CAP1	2
CAPN2	5
CARD11	4
CASP7	3
CASP8	2
CBR3	3
CBX3	3
CD37	2
CD46	4
CD79B	2
CDC25A	3
CDC42	5
CDK12	3
CDK16	3
CDK19	7
CDK2AP1	1
CELF1	2

UCSC_RefGene_Name	PCHorvath2 EAA	PCHannum EAA	PCGrimAge EAA	DamAge EAA	IntrinClock EAA	Stoch Zhang EAA	Stoch Horvath EAA	Stoch PhenoAge EAA	RetroClock V1/2 EAA	Inflammation	Cognition	Type 2 Diabetes	Obesity	M1 polarization	Kinase Cascade	Lipids	Glycolysis	Phosphoprotein	Nominated	Chromatin Reg.	Transcription	Shared	AD Proteomics	PD Proteomics	FTD Proteomics	Dementia Transcripts	Braak Transcripts	TF transcribing PBDPM genes	Transcribed by PBDPM TF	No significant TF association
CENPM																	○					1							○	
CEP55																	○					1							○	
CFL2										●												1	●						●	
CHAC1										●												1							●	
CHD1L										●												1	●						●	
CHEK2										●			●	●			●					4	●	●	●	●			●	
CHPF										●	●		●				●					4							●	
CLIC5										●			●									2	●	●	●				●	
CMPK2										●					●							2							●	
CPEB3											○			○			○					3							○	
CREB1										●		●	●		●	●	●				●	7						●	●	
CREB3L2										●					●						●	3							●	
CREBZF										●			●	●							●	5							●	
CRY1													○				○					2							○	
CRYZ												🟢										1							🟢	
CSNK1A1												○			○							2							○	
CSNK1D					●	●	●			●	●				●							6	●						●	
CSNK1G3							●			●					●							3							●	
CSNK2B										●					●							3							●	
CSRP1										●						●			●			3	●		●				●	
CTSC										●	●			●	●							4					●		●	
CTSL										●				●	●							3							●	
CUTA											○											1	○							
DAPK2										●					●			●				3							●	
DBI										●	●											2				●	●		●	
DBT										●	●	●							●			4	●						●	
DCAF6										●												1							●	
DDB2										●							●			●	●	5							●	
DDX20										●				●								3							●	
DDX41										●			●									3							●	
DDX46										●						●						3		●					●	
DDX5										●	●		●			●					●	5							●	
DEDD2										●												2							●	
DENND1B											○	○	○						○			4							○	
DGAT1										●	●	●	●			●						5							●	
DGKZ							○				○	○	○			○	○					6							○	
DHX16										●			●									2							●	
DIABLO										●												1	●						●	
DLG4										●												1							●	
DLX2										●						●				●	●	4							●	
DPP4										●	●	●	●	●	●							6							●	
DUSP2										●				●						●		3	●						●	
DUSP22										🟢	🟢		🟢	🟢	🟢	🟢	🟢			🟢		8					🟢		🟢	
E2F2						●				●			●		●	●					●	6						●	●	
E2F7										●					●			●			●	4							●	
E2F8												○					○	○		○		4							○	
EARS2										●	●	●	●	●		●						6								
ECHDC1										●		●				●						3		●	●					
EFNA4				●						●		●	●									6		●	●	●				
EGR1										●	●	●		●						●	●	5							●	
EGR2										●	●	●								●	●	6							●	
EHMT1										●	●	●								●		4							●	
EHMT2										●	●	●				●					●	6	●		●				●	
EIF1AD										●												1	●						●	
EIF2AK3										●			●	●	●							4							●	
EIF4E							●			●	●		●	●		●	●	●				8		●	●				●	
EIF5A										●	●	●	●		●	●						6	●	●	●				●	
ELF1										●					●						●	4						●	●	
ELOVL1										●	●				●							4							●	
EML2										●												1							●	
ENO3											○				○				○			4							○	
EPHA4										●	●		●	●								4							●	
ERBB2										●	●	●	●									8	●						●	
ETV1										●										●	●	4						●	●	
EXPH5											○											1							○	
FAM163A																○		○				2							○	
FBXL16	🟢				🟢					🟢	🟢	🟢		🟢		🟢		🟢				7							🟢	
FDPS										●	●		●			●						4	●	●					●	
FGD6										●												1							●	
FKBP1A										●	●	●	●									4	●						●	
FLII										●	●											2	●						●	
FLNA										●				●							●	3	●						●	
FOSB										●	●	●	●	●						●	●	8							●	
FOXJ2										●	●	●								●	●	7							●	
FOXO4										●	●	●								●	●	5	●	●					●	

Legend for cell markers: R = red filled circle, G = green filled circle, O = grey/open circle.

UCSC_RefGene_Name	PCHorvath2 EAA	PCHannum EAA	PCGrimAge EAA	DamAge EAA	IntrinClock EAA	Stoch Zhang EAA	Stoch Horvath EAA	Stoch PhenoAge EAA	RetroClock V1/2 EAA	Inflammation	Cognition	Type 2 Diabetes	Obesity	M1 polarization	Kinase Cascade	Lipids	Glycolysis	Phosphoprotein	Nominated	Chromatin Reg.	Transcription	Shared	AD Proteomics	PD Proteomics	FTD Proteomics	Dementia Transcripts	Braak Transcripts	TF transcribing PBDPM genes	Transcribed by PBDPM TF	No significant TF association
LHPP											O											1							O	
LIME1										R												1							R	
LINC01126										R					R							2								R
LINC01806											G	G										2								G
LIPG										R	R		R	R		R						5			R				R	
LPCAT4										R				R								2			R				R	
LZTFL1										R					R							2	R	R					R	
MAF1											O		O								O	3				O	O	O	O	
MAGT1															O			O				2							R	
MAML1										R	R				R					R	R	5							R	
MAMSTR										G	G										G	3							G	
MAN2A2												O										1								
MAP2K1										R	R			R	R	R						6							R	
MAP2K3					R			R		R	R	R	R	R	R							8							R	
MAP2K6										R	R	R	R	R	R	R						7							R	
MAP3K12										R	R	R	R	R	R							6							R	
MAP4K1										R	R		R		R							4							R	
MAP4K5										R			R		R							3							R	
MARK2										R	R		R	R	R	R						6							R	
MARK3										R				R	R			R				4							R	
MAT2A										R		R	R		R			R		R		6							R	
MATR3																		O				1							O	
MBNL1	R					R	R			R		R	R		R	R						6					R		R	
MCM2										R				R		R						3							R	
MECP2										R	R		R							R		4	R						R	
MGAT1										R	R	R		R								4				R	R		R	
MIA3										R												1					R		R	
MICB										R												1							R	
MIR4458HG													G									1								G
MKRN1											O	O			O							3							O	
MLF1										R												1	R						R	
MPC1										R	R											2	R						R	
MPI						O					O						O					3							O	
MTHFR										R	R	R	R		R							5							R	
MTOR					R					R	R	R	R	R	R							8							R	
MTTP										R		R	R	R		R						5							R	
MUTYH										R								R				2							R	
MYL12A										R				R				R				3		R					R	
MYO1G										R												1								
N4BP2L1												O										1							O	
NAGK										R					R							2	R						R	
NARF										R			R									2	R						R	
NEAT1					R				R	R	R	R	R	R	R	R						10							R	
NEU1										R				R								2	R	R					R	
NFE2L2										R		R		R	R					R	R	7				R			R	
NFKB2										R	R		R		R					R	R	6							R	
NFKBIA										R		R	R	R	R	R		R				8	R	R					R	
NFKBIZ										R	R	R	R	R	R			R	R	R		9							R	
NFYC												O						O			O	3							R	
NINJ2										R					R							3							R	
NLRP1										R	R				R			R				5		R					R	
NME3										G				G								2							G	
NOTCH4										R			R		R							3							R	
NR3C1											O	O	O						O	O	O	6						O	O	
NR3C2										R		R						R			R	4						R	R	
NRBP1			R							R	R			R								4	R						R	
NUBP1										R												1	R						R	
OCIAD1										R								R				3							R	
OSBPL11											O		O			O		O				3							R	
P2RX1										R		R		R	R							5							R	
PAFAH1B3										R	R											2	R	R	R				R	
PAK1										R			R	R	R	R		R				8							R	
PARD6G-AS1											G											1						G		G
PBX3										R	R		R							R		5	R			R	R		R	
PCK2										R	R		R									3	R	R					R	
PDE7A										R	R											2	R						R	
PDK3												R	R		R	R						5							R	
PDZD8											O											1							O	
PEG10												O					O					2							O	
PEMT											O	O										2							O	
PFKFB4										R		R		R		R						5							R	
PFKP										R	R	R	R	R	R			R				7				R	R		R	
PGD										R												1	R	R	R				R	
PGM1												O				O	O					3							O	
PGPEP1										R												1							R	

UCSC_RefGene_Name	PCHorvath2 EAA	PCHannum EAA	PCGrimAge EAA	DamAge EAA	IntrinClock EAA	Stoch Zhang EAA	Stoch Horvath EAA	Stoch PhenoAge EAA	RetroClock V1/2 EAA	Inflammation	Cognition	Type 2 Diabetes	Obesity	M1 polarization	Kinase Cascade	Lipids	Glycolysis	Phosphoprotein	Nominated	Chromatin Reg.	Transcription	Shared	AD Proteomics	PD Proteomics	FTD Proteomics	Dementia Transcripts	Braak Transcripts	TF transcribing PBDPM genes	Transcribed by PBDPM TF	No significant TF
PGRMC1													○			○	○	○				4	○						○	
PHACTR1										●				●	●	●						4							●	
PIK3R1										●	●			●	●	●						5							●	
PIK3R3										●	●			●	●	●						5							●	
PIK3R5										●	●			●	●	●						5							●	
PIM3										●		●			●							4							●	
PIP4K2B												○	○			○	○					4							○	
PITX1										●											●	2						●	●	
PKM										●	●			●	●		●	●				7	●	●	●				●	
PKNOX1										●	●	●		●			●				●	6							●	
PLAU												●		●								3							●	
PLCG2														●	●				●			4	●						●	
PLSCR2										🟢				🟢								2							🟢	
PLXNC1										●	●		●									3		●	●				●	
POLR2A										●								●		●	●	4						●	●	
POU2F2											○						○		●		○	3						○	○	
PPP1R13L											○											1				○			●	
PPP3CB										●		●			●							4							●	
PQBP1										●										●		2	●						●	
PRDX5										●				●								2	●	●					●	
PRKAB2													○	○	○		○					4							○	
PRKCA										●	●	●		●	●				●			8		●					●	
PRKCI										●	●				●							3							●	
PRKD2										●	●			●	●							6							●	
PRKRA										●	●			●	●							4	●						●	
PRKRIP1									●	●	●				●							4							●	
PSMA1										●												1							●	
PSMB1										●			●	●								4							●	
PSMB10										●			●	●			●					5							●	
PSMB3										●												2	●	●					●	
PSMB9										●												1							●	
PSMC5										●				●								3	●	●					●	
PTEN												○	○			○				○		4							○	
PTGER2	●						●			●	●		●	●	●							6							●	
PTK2B			●							●	●	●		●	●		●		●			9	●						●	
PTPN6	●									●	●	●							●		●	6	●						●	
QRICH1										●	●			●							●	4							●	
RAC1										●	●	●	●	●	●	●	●					9		●	●				●	
RAI14											●				●							2							●	
RBBP4											●				●							3	●						●	
RBM15										●		●		●		●	●					6							●	
RBM23										●	●											2	●						●	
RFX5										●											●	2	●				●		●	
RGS2												○						○				2							○	
RLIM													○		○							3							○	
RNF144B										●												1							●	
RNF31										●				●								2		●					●	
RNF4										●										●		2							●	
RNY3																						1				●	●	●		●
RUNX2								●			●									●	●	5							●	
SAT1				●						●	●		●			●						5		●					●	
SAT2										●	●											2	●						●	
SCO2										●			●				●	●				4							●	
SELPLG										●				●	●	●	●					6							●	
SERBP1											○							○				2							○	
SERPINB6											○											1				○			○	
SF3A2										●				●								2							●	
SF3A3										●				●								2							●	
SGK3											○		○			○		○		○		6	○	○	○				○	
SH2B3										●												1		●					●	
SH3BGRL2												○										1	○						○	
SH3GLB2										●	●								●			3							●	
SIRT2										●	●	●	●								●	5	●						●	
SIVA1											○			●			○	○				4							○	
SLC15A4										●				●								2							●	
SLC1A5																●			○			2				○			○	
SLC25A12											○											1							○	
SLC25A43																		○				1							○	
SLC28A2-AS1										🟢												1								🟢
SLC9A7											○											1				○	○		○	
SLC9B2												🟢		🟢		🟢						3							🟢	
SLU7										●	●							●				3							●	
SMAD1										●	●		●		●					●	●	6						●	●	
SMAD3										●	●	●	●	●	●					●	●	12	●		●			●	●	
SMARCC1												●		●		●				●	●	6		●					●	

Figure 4. Shared genes for all 448 PBDPM genes. Shared genes as in Figure 3.

A   **Additional examples of bezisterim potentially beneficial DMP gene correlations with clinical measures**

B   **Examples of placebo potential risk DMP gene correlations with clinical measures**

Figure 5. Gene and clinical measures correlations. (A) Examples of significant bezisterim clinical measures and DPM gene correlations. Clinical activity for neurologic assessments are shown with an example of the bezisterim and the placebo subject correlations for a single gene. **(B)** Examples of significant placebo clinical measure and DPM gene correlations. Three correlations of GFAP with individual genes (GPD2, IRF1, and P2RX1), and 3 correlations of the

gene NINJ2 with clinical measures (ADCOMS, Cog12, and GST) and displayed. Decreases in the sum of placebo promoter methylation compared to bezisterim subjects increases assessment decline risk.

Figure 6. Systolic blood pressure correlations. Graphs of Pearson correlations for 6 genes significantly positively correlated to placebo systolic blood pressure. The red boxes demonstrate that decreased methylation of 6 genes was associated with lower systolic blood pressure in placebo subjects compared to bezisterim subjects that may result in decreased brain perfusion

Supporting Information

Additional supporting information can be found in Supplementary Files 1-4:

- **Supplemental file 1**
  - Table S1. Differential promoter methylation (DPM) gene investigations
  - Table S2a. Master Table of DPM genes
  - Table S2b. Master Figure of DPM genes

- **Supplemental file 2**
  - Table S3. PCHorvath2.EAA
  - Table S4. PCHannum.EAA
  - Table S5. PCGrimAge.EAA
  - Table S6. DamAge.EAA
  - Table S7. IntrinClock.EAA
  - Table S8. StocZhang.EAA
  - Table S9. StocHorvath.EAA
  - Table S10. StocPhenoAge.EAA
  - Table S11. RetroClockV1&2
  - Table S12. Inflammation
  - Table S13. Cognition
  - Table S14. T2D
  - Table S15. Obesity
  - Table S16. M1 polarization
  - Table S17. Kinase cascades
  - Table S18. Lipids
  - Table S19. Glycolysis
  - Table S20. Phosphoproteins
  - Table S21. Nominated targets
  - Table S22. Chromatin remodeling
  - Table S23. Transcription factors
  - Table S24. AD proteomics
  - Table S25. PD proteomics

- o Table S26. FTD proteomics
- o Table S27. Dementia transcripts
- o Table S28. Braak transcripts
- o Table S29. Transcription factors
- o Table S30. ChEA_2022_
- o Table S31. ENCODE
- o Table S32. ChEA clock
- o Table S33. ENCODE clock
- **Supplemental file 3. Links and additional information**
- **Supplemental file 4. Clinical gene correlations**
  - o Table S34. Description of clinical measures used for correlations
  - o Table S35. Bezisterim FDR < 0.05 significant correlations
  - o Table S36. Placebo FDR < 0.05 significant correlations
  - o Table S37. Bezisterim FDR < 0.05 multiple genes for same clinical measure
  - o Table S38. Placebo FDR < 0.05 multiple genes for same clinical measure
  - o Table S39. Bezisterim FDR < 0.05 correlations Z-score P vs placebo correlations
  - o Table S40. Placebo FDR < 0.05 correlations Z-score P vs bezisterim correlations
  - o Table S41. Bezisterim FDR < 0.01 correlation gene sharing & clinical measures
  - o Table S42. Placebo FDR < 0.01 correlation gene sharing & bezisterim measures